<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction - Martin, N - 2021 | Cochrane Library</title> <meta content="Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction - Martin, N - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction - Martin, N - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012721.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction" name="citation_title"/> <meta content="Nicole Martin" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Karthick Manoharan" name="citation_author"/> <meta content="John Radcliffe Hospital" name="citation_author_institution"/> <meta content="Ceri Davies" name="citation_author"/> <meta content="Barts Heart Centre, St Bartholomew's Hospital" name="citation_author_institution"/> <meta content="R Thomas Lumbers" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="t.lumbers@ucl.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012721.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta-Antagonists [*therapeutic use]; Angiotensin Receptor Antagonists [*therapeutic use]; Angiotensin-Converting Enzyme Inhibitors [*therapeutic use]; Chronic Disease; Heart Failure [*drug therapy, mortality]; Hospitalization; Mineralocorticoid Receptor Antagonists [*therapeutic use]; Neprilysin [antagonists &amp; inhibitors]; Quality of Life; Randomized Controlled Trials as Topic; Renin-Angiotensin System [*drug effects]; *Stroke Volume" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012721.pub3&amp;doi=10.1002/14651858.CD012721.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012721\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012721\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ms","ja","hr","fa","fr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012721.pub3",title:"Beta\\u2010blockers and inhibitors of the renin\\u2010angiotensin aldosterone system for chronic heart failure with preserved ejection fraction",firstPublishedDate:"May 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012721.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012721.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012721.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012721.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012721.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012721.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012721.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012721.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012721.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012721.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7037 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012721.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0107"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-sec-0096"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/appendices#CD012721-sec-0112"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/supinfo/CD012721StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/supinfo/CD012721StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#CD012721-cr-0004">Nicole Martin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#CD012721-cr-0005">Karthick Manoharan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#CD012721-cr-0006">Ceri Davies</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information#CD012721-cr-0007"><i class="icon corresponding-author fa fa-envelope"></i>R Thomas Lumbers</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information/en#CD012721-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012721.pub3">https://doi.org/10.1002/14651858.CD012721.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012721-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012721-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012721-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012721-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012721-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012721-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012721-abs-0001" lang="en"> <section id="CD012721-sec-0001"> <h3 class="title" id="CD012721-sec-0001">Background</h3> <p>Beta‐blockers and inhibitors of the renin‐angiotensin‐aldosterone system improve survival and reduce morbidity in people with heart failure with reduced left ventricular ejection fraction (LVEF); a review of the evidence is required to determine whether these treatments are beneficial for people with heart failure with preserved ejection fraction (HFpEF). </p> </section> <section id="CD012721-sec-0002"> <h3 class="title" id="CD012721-sec-0002">Objectives</h3> <p>To assess the effects of beta‐blockers, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor neprilysin inhibitors, and mineralocorticoid receptor antagonists in people with HFpEF. </p> </section> <section id="CD012721-sec-0003"> <h3 class="title" id="CD012721-sec-0003">Search methods</h3> <p>We updated searches of CENTRAL, MEDLINE, Embase, and one clinical trial register on 14 May 2020 to identify eligible studies, with no language or date restrictions. We checked references from trial reports and review articles for additional studies.  </p> </section> <section id="CD012721-sec-0004"> <h3 class="title" id="CD012721-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials with a parallel group design, enrolling adults with HFpEF, defined by LVEF greater than 40%. </p> </section> <section id="CD012721-sec-0005"> <h3 class="title" id="CD012721-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD012721-sec-0006"> <h3 class="title" id="CD012721-sec-0006">Main results</h3> <p>We included 41 randomised controlled trials (231 reports), totalling 23,492 participants across all comparisons. The risk of bias was frequently unclear and only five studies had a low risk of bias in all domains. </p> <p><b>Beta‐blockers (BBs)</b> </p> <p>We included 10 studies (3087 participants) investigating BBs. Five studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 30 years to 81 years. </p> <p>A possible reduction in cardiovascular mortality was observed (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.62 to 0.99; number needed to treat for an additional benefit (NNTB) 25; 1046 participants; three studies), however, the certainty of evidence was low. There may be little to no effect on all‐cause mortality (RR 0.82, 95% CI 0.67 to 1.00; 1105 participants; four studies; low‐certainty evidence). The effects on heart failure hospitalisation, hyperkalaemia, and quality of life remain uncertain. </p> <p><b>Mineralocorticoid receptor antagonists (MRAs)</b> </p> <p>We included 13 studies (4459 participants) investigating MRA. Eight studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 54.5 to 80 years. </p> <p>Pooled analysis indicated that MRA treatment probably reduces heart failure hospitalisation (RR 0.82, 95% CI 0.69 to 0.98; NNTB = 41; 3714 participants; three studies; moderate‐certainty evidence). However, MRA treatment probably has little or no effect on all‐cause mortality (RR 0.91, 95% CI 0.78 to 1.06; 4207 participants; five studies; moderate‐certainty evidence) and cardiovascular mortality (RR 0.90, 95% CI 0.74 to 1.11; 4070 participants; three studies; moderate‐certainty evidence). MRA treatment may have little or no effect on quality of life measures (mean difference (MD) 0.84, 95% CI ‐2.30 to 3.98; 511 participants; three studies; low‐certainty evidence). MRA treatment was associated with a higher risk of hyperkalaemia (RR 2.11, 95% CI 1.77 to 2.51; number needed to treat for an additional harmful outcome (NNTH) = 11; 4291 participants; six studies; high‐certainty evidence). </p> <p><b>Angiotensin‐converting enzyme inhibitors (ACEIs)</b> </p> <p>We included eight studies (2061 participants) investigating ACEIs. Three studies used a placebo comparator and in five the comparator was usual care. The mean age of participants ranged from 70 to 82 years. </p> <p>Pooled analyses with moderate‐certainty evidence suggest that ACEI treatment likely has little or no effect on cardiovascular mortality (RR 0.93, 95% CI 0.61 to 1.42; 945 participants; two studies), all‐cause mortality (RR 1.04, 95% CI 0.75 to 1.45; 1187 participants; five studies) and heart failure hospitalisation (RR 0.86, 95% CI 0.64 to 1.15; 1019 participants; three studies), and may result in little or no effect on the quality of life (MD ‐0.09, 95% CI ‐3.66 to 3.48; 154 participants; two studies; low‐certainty evidence). The effects on hyperkalaemia remain uncertain. </p> <p><b>Angiotensin receptor blockers (ARBs)</b> </p> <p>Eight studies (8755 participants) investigating ARBs were included. Five studies used a placebo comparator and in three the comparator was usual care. The mean age of participants ranged from 61 to 75 years. </p> <p>Pooled analyses with high certainty of evidence suggest that ARB treatment has little or no effect on cardiovascular mortality (RR 1.02, 95% 0.90 to 1.14; 7254 participants; three studies), all‐cause mortality (RR 1.01, 95% CI 0.92 to 1.11; 7964 participants; four studies), heart failure hospitalisation (RR 0.92, 95% CI 0.83 to 1.02; 7254 participants; three studies), and quality of life (MD 0.41, 95% CI ‐0.86 to 1.67; 3117 participants; three studies). ARB was associated with a higher risk of hyperkalaemia (RR 1.88, 95% CI 1.07 to 3.33; 7148 participants; two studies; high‐certainty evidence). </p> <p><b>Angiotensin receptor neprilysin inhibitors (ARNIs)</b> </p> <p>Three studies (7702 participants) investigating ARNIs were included. Two studies used ARBs as the comparator and one used standardised medical therapy, based on participants' established treatments at enrolment. The mean age of participants ranged from 71 to 73 years. </p> <p>Results suggest that ARNIs may have little or no effect on cardiovascular mortality (RR 0.96, 95% CI 0.79 to 1.15; 4796 participants; one study; moderate‐certainty evidence), all‐cause mortality (RR 0.97, 95% CI 0.84 to 1.11; 7663 participants; three studies; high‐certainty evidence), or quality of life (high‐certainty evidence). However, ARNI treatment may result in a slight reduction in heart failure hospitalisation, compared to usual care (RR 0.89, 95% CI 0.80 to 1.00; 7362 participants; two studies; moderate‐certainty evidence). ARNI treatment was associated with a reduced risk of hyperkalaemia compared with valsartan (RR 0.88, 95% CI 0.77 to 1.01; 5054 participants; two studies; moderate‐certainty evidence). </p> </section> <section id="CD012721-sec-0007"> <h3 class="title" id="CD012721-sec-0007">Authors' conclusions</h3> <p>There is evidence that MRA and ARNI treatment in HFpEF probably reduces heart failure hospitalisation but probably has little or no effect on cardiovascular mortality and quality of life. BB treatment may reduce the risk of cardiovascular mortality, however, further trials are needed. The current evidence for BBs, ACEIs, and ARBs is limited and does not support their use in HFpEF in the absence of an alternative indication. Although MRAs and ARNIs are probably effective at reducing the risk of heart failure hospitalisation, the treatment effect sizes are modest. There is a need for improved approaches to patient stratification to identify the subgroup of patients who are most likely to benefit from MRAs and ARNIs, as well as for an improved understanding of disease biology, and for new therapeutic approaches.   </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012721-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012721-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012721-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012721-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012721-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012721-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012721-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012721-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ro#CD012721-abs-0012">Română</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012721-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012721-abs-0002" lang="en"> <h3>Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction </h3> <p><b>Review question</b> </p> <p>We investigated the effects of beta‐blockers (BBs), mineralocorticoid receptor antagonists (MRAs), angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and angiotensin receptor neprilysin inhibitors (ARNIs) on survival, hospital admissions for heart failure, quality of life and potassium levels in people with heart failure with preserved ejection fraction (HFpEF). </p> <p><b>Background</b> </p> <p>Heart failure is a common condition that occurs when the function of the heart muscle is impaired, being associated with symptoms of breathlessness and fatigue, and a reduction in survival. In around half of cases of heart failure, where the left ventricular ejection fraction is reduced to less than 40% (reflecting significant impairment of contractile function), several drug treatments are known to be effective at improving survival and reducing hospitalisation. In the remaining cases, where the ejection fraction is normal or only mildly reduced (HFpEF), it is not clear whether the same drug treatments are effective at improving outcomes. </p> <p><b>Selection criteria</b> </p> <p>We sought to investigate whether treatments for heart failure with reduced ejection fraction are also effective in HFpEF. We conducted a comprehensive search for all trials investigating BBs, MRAs, ACEIs, ARBs or ARNIs (evidence current to 14 May 2020). </p> <p><b>Results and conclusions</b> </p> <p>We included 10 studies with 3087 randomised participants for BBs, 13 studies with 4459 randomised participants for MRAs, eight studies with 2061 randomised participants for ACEIs, eight studies with 8755 randomised participants for ARBs and three studies with 7702 randomised participants for ARNIs. We combined the evidence in a pooled analysis for each drug class and for each of the outcomes assessed. Not all included studies are part of each analysis. </p> <p>We found that BBs may improve cardiovascular mortality. However, the certainty of evidence was low due to small trials and uncertainty about the methods used. For MRAs, the results suggest a reduction in heart failure hospitalisation but little or no effect on cardiovascular and all‐cause mortality; however, the certainty of evidence was only moderate. For ACEIs, treatment probably has little or no effect on the outcomes of cardiovascular mortality, all‐cause mortality and heart failure hospitalisation; however, the certainty of evidence was only moderate. We found high certainty of evidence for ARB treatment, with the results suggesting little or no effect. We found that ARNI treatment has little or no effect on cardiovascular mortality (moderate‐certainty evidence), all‐cause mortality (high‐certainty evidence), or quality of life (high‐certainty evidence). ARB treatment may reduce slightly heart failure hospitalisations (moderate‐certainty evidence). Treatment with MRAs and ARBs was found to increase the risk of high potassium in the blood. </p> <p>In conclusion, treatment with MRAs, and possibly ARNIs, was found to result in a slight reduction in the risk of hospitalisation due to heart failure. There was some evidence of a possible beneficial effect of BB on mortality due to cardiovascular disease. Treatment with ACEI probably has no beneficial effect in people with HFpEF, however, this remains uncertain due to a lack of evidence from clinical trials. For ARBs, the evidence suggested that treatment is of little or no benefit in people with HFpEF. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of evidence ranged from high to low across the outcomes and drug classes studied. With the exception of ARBs and ARNIs, there was a lack of large‐scale trials in HFpEF for the interventions and outcomes tested. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012721-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012721-sec-0107"></div> <h3 class="title" id="CD012721-sec-0108">Implications for practice</h3> <section id="CD012721-sec-0108"> <p>Our findings suggest that MRA and ARNI treatments have a modest beneficial effect on the risk of heart failure hospitalisation and that BB may reduce the risk of cardiovascular mortality. We did not find evidence supporting an important beneficial effect of ARBs (high‐certainty evidence), or ACEIs (moderate‐certainty evidence) on mortality and hospitalisation outcomes. Although we were not able to stratify our analysis by LVEF, we note evidence from individual‐participant level meta‐analyses that suggest benefit from BB, MRA, and ARNI treatment in heart failure patients with LVEF 40 to 49%, in addition to those with LVEF &lt; 40%. For all comparisons, no effect on the quality of life was observed, although the certainty of the evidence was low.  </p> </section> <h3 class="title" id="CD012721-sec-0109">Implications for research</h3> <section id="CD012721-sec-0109"> <p>This review highlights persistent uncertainty concerning the effects of BBs, MRAs, ACEIs, and ARNIs in HFpEF, defined as LVEF greater than 40%. Although we were unable to explore LVEF as an effect modifier in this study‐level review and meta‐analysis, reports of individual participant‐level pooled analyses of BBs and RAAS inhibition suggest that beneficial effects may extend beyond patients with reduced ejection fraction (LVEF less than 40%) heart failure, to include patients with heart failure with mid‐range ejection fraction (LVEF 40% to 49%; HFmrEF). It is possible that heart failure patients with normal or increased LVEF have distinct aetiopathology. For example, a recent study found that one in seven patients with HFpEF had evidence of wild‐type transthyretin amyloidosis (<a href="./references#CD012721-bbs2-0386" title="Gonzalez-LopezE , Gallego-DelgadoM , Guzzo-MerelloG , deHaro-Del MoralFJ , Cobo-MarcosM , RoblesC , et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. European Heart Journal2015;36(38):1285-94.">Gonzalez‐Lopez 2015</a>). The application of precision phenotyping at a population‐scale may yield important information about the disease mechanisms underlying onset and progression in these patients, and provide the basis for the development of more effective therapeutic approaches. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012721-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012721-sec-0008"></div> <div class="table" id="CD012721-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> beta‐blockers<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range 21 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.62 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1046<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three additional studies (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/>(107 to 171) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 6 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.47 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>449<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up unclear for <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> reported that no hospitalisation due to heart failure occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/>(55 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> <p>follow‐up: mean 3.2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> reported one participant in the intervention group (N = 120) experienced hyperkalaemia but did not report on this outcome for the control group. No further data were available from any of the other studies. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow‐up: range 21 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.67 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1105<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up unclear for <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>, <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a> and <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a> reported that no deaths occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000<br/>(163 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) was 24</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/>(9.05 lower to 7.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower = better, 5 point difference considered to be clinically meaningful</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to study limitations (unclear selection bias in most studies). </p> <p><sup>2</sup>Downgraded by one level due to imprecision (concerns about the smaller study being more precise than the larger study). </p> <p><sup>3</sup>Downgraded by two levels due to imprecision (few events and wide CI). </p> <p><sup>4</sup>Downgraded by two levels due to imprecision (very small sample size). </p> <p><sup>5</sup>Downgraded by one level due to suspected publication bias (this is a patient‐relevant outcome that is not reported in most studies). </p> <p><sup>6</sup>Downgraded by two levels due to suspected publication bias (incomplete reporting). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012721-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MRAs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> MRAs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MRAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range 12 months to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.74 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4070<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two additional trials (<a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(65 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 24 weeks to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.69 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3714<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three additional trials (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) reported that no hospitalisation due to heart failure occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/>(94 to 134) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hyperkalaemia<br/>follow‐up: range 24 weeks to 3.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.11<br/>(1.77 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4291<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two trials defined hyperkalaemia ≥ 5.5 mEg/L</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000<br/>(146 to 208) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow‐up: range 9 months to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.78 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4207<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two additional trials (<a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000<br/>(104 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: range 9 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 20 to 25</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.84 higher<br/>(2.30 lower to 3.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower = better, 5 points are considered a clinically significant difference</p> <p>We did not pre‐specify which QoL scale was to be reported in the 'Summary of findings' table. To aid comparisons among 'Summary of findings' tables we chose to include the Minnesota Living with Heart Failure questionnaire and not the SMD across two scales </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>MRAs:</b> Mineralocorticoid receptor antagonists; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision. </p> <p><sup>2</sup>Downgraded by one level due to study limitations (one trial was open label). </p> <p><sup>3</sup>Downgraded by one level due to imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012721-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ACEIs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ACEIs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ACEI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range mean 12 months to mean 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.61 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>945<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(53 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 6 months to 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.64 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1019<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(8 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> <p>follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (1 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One trial (<a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) reported 2 events in the intervention group (N = 36), 0 events in the control group (N = 38) (RR 5.27, 95% CI 0.26 to 106.16) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow‐up: range mean 6 months to mean 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.75 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1187<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(77 to 148) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 10.9 to 29</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/>(3.66 lower to 3.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale: 0 to 105, lower = better, 5 point difference considered clinically relevant</p> <p>One trial (<a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>) reported mean change from baseline of ‐19.8 for intervention and ‐10.7 for control </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACEIs:</b> Angiotensin‐converting enzyme inhibitors; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (wide CI). </p> <p><sup>2</sup>Downgraded by one level due to study limitations (risk of bias (open label)). </p> <p><sup>3</sup>Downgraded by one level due to imprecision (low sample size). </p> <p><sup>4</sup>Downgraded by one level due to study limitations (unclear selection bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012721-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARBs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ARBs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ARBs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range mean 12 months to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.90 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7254<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(118 to 149) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range mean 12 months to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.83 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7254<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1,‐000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1,‐000<br/>(142 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hyperkalaemia<br/>follow‐up: range 36.6 months to 49.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.88<br/>(1.07 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1,000<br/>(3 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow up: range 1 years to 4.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.92 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7964<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1,‐000<br/>(66 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: range mean 13.8 weeks to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 10.9 to 31.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.41 higher<br/>(0.86 lower to 1.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3117<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale: 0 to 105, lower = better, 5 point difference considered clinically relevant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ARBs:</b> Angiotensin receptor blockers; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD012721-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Angiotensin receptor neprilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARNIs compared to usual care for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ARNI (sacubitril‐valsartan)<br/><b>Comparison:</b> ARB <b>(</b>valsartan) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ARNI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)</p> <p>Median follow‐up: 35 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.79 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4796<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000<br/>(70 to 102) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Heart failure hospitalisation, first (RR)</p> <p>Range of follow‐up: 24 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.89</p> <p>(0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7362</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>126 per 1,000</p> <p>(113 to 142)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hyperkalaemia</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.88<br/>(0.77 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5054<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>147 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>129 per 1,000<br/>(113 to 148) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 0.97</p> <p>CI 0.84 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7663<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/>(117 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a> reported change from baseline for the KCCQ overall summary score for the intervention arm (n =118) as 11.25 (2.185) and the control arm (n = 116) as 11.31 (2.183) and summarised the findings as "no difference in KCCQ score between treatment groups". </p> <p><a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> reported a difference of the clinical summary score KCCQ between treatment arms as 1.0 (0.0 to 2.1). </p> <p><a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> reported "KCCQ improved in both treatment groups, with an early benefit of S/V that was no longer significant after 24 week". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ARB:</b> Angiotensin receptor blocker; <b>ARNIs:</b> Angiotensin receptor neprilysin inhibitors; <b>CI:</b> Confidence interval; <b>KCCQ:</b> Kansas City Cardiomyopathy Questionnaire; <b>MD:</b> Mean difference; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012721-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012721-sec-0009"></div> <section id="CD012721-sec-0010"> <h3 class="title" id="CD012721-sec-0010">Description of the condition</h3> <p>Heart failure is a clinical syndrome characterised by breathlessness and fatigue that results when abnormalities of cardiac structure and function lead to inadequate cardiac output, elevated ventricular filling pressures, or both (<a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). Based on available data from the United States and Europe, the prevalence of heart failure is estimated to range from 1% to 12% of the adult population and is projected to increase with populations ageing and with improved survival from cardiovascular disease (<a href="./references#CD012721-bbs2-0407" title="RogerVL . Epidemiology of heart failure. Circulation Research2013;113(6):646-59.">Roger 2013</a>). Heart failure represents a significant public health problem, accounting for 5% of emergency medical admissions to hospital in the United Kingdom (<a href="./references#CD012721-bbs2-0397" title="NICE. Chronic heart failure in adults: diagnosis and management. www.nice.org.uk/guidance/ng106 (accessed 2 October 2020).">NICE 2018</a>). It is associated with significant mortality risk, with a ten‐year survival of 27%, compared with 75% in the general population, matched for age and sex (<a href="./references#CD012721-bbs2-0417" title="TaylorCJ , RoalfeAK , IlesR , HobbsFD . Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. European Journal of Heart Failure2012;14(2):176-84.">Taylor 2012</a>). Heart failure is classified according to the left ventricular ejection fraction (LVEF) into two categories: heart failure with reduced ejection fraction (HFrEF, typically considered as LVEF less than 40%), and heart failure with preserved ejection fraction (HFpEF, typically LVEF greater than 40%). Recently, an intermediate subgroup was defined by the European Society of Cardiology as heart failure with mid‐range ejection fraction (HFmrEF) defined as LVEF 40% to 49% (<a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). This was defined by the American College of Cardiology as borderline HFpEF, defined as LVEF 41% to 49% (<a href="./references#CD012721-bbs2-0419" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardioliology2013;62(16):e147-239.">Yancy 2013</a>). In this review, we defined HFpEF as LVEF greater than 40% because completed and ongoing HFpEF trials have used a range of LVEF cut‐offs, between 40% and 50%. HFpEF accounts for approximately half of all cases of HF; mortality outcomes are similar to those for HFrEF (<a href="./references#CD012721-bbs2-0385" title="Gerber Yariv, Weston SusanA , Redfield MargaretM , Chamberlain AlannaM , Manemann SheilaM , Jiang Ruoxiang, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine2015;175(6):996.">Gerber 2015</a>). </p> </section> <section id="CD012721-sec-0011"> <h3 class="title" id="CD012721-sec-0011">Description of the intervention</h3> <p>Neurohumoral inhibition with beta‐blockers (BB), angiotensin converting enzyme inhibitors (ACEIs), and mineralocorticoid receptor antagonists (MRAs) leads to improved survival and a reduction in hospitalisations for heart failure in people with HFrEF (<a href="./references#CD012721-bbs2-0376" title="IICIBIS . The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353(9146):9-13.">CIBIS Investigators 1999</a>; <a href="./references#CD012721-bbs2-0379" title="Group CONSENSUS Trial Study. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine1987;316(23):1429-35.">Consensus Trial Study Group 1987</a>; <a href="./references#CD012721-bbs2-0384" title="FlatherMD , ShibataMC , CoatsAJ , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26(3):215-25.">Flather 2005</a>; <a href="./references#CD012721-bbs2-0389" title="HjalmarsonA , GoldsteinS , FagerbergB , WedelH , WaagsteinF , KjekshusJ , et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA2000;283(10):1295-302.">Hjalmarson 2000</a>; <a href="./references#CD012721-bbs2-0392" title="KotechaD , HolmesJ , KrumH , AltmanDG , ManzanoL , ClelandJGF , et al, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet2014;384(9961):2235-43.">Kotecha 2014</a>; <a href="./references#CD012721-bbs2-0396" title="MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet1999;353(9169):2001-7.">MERIT‐HF Study Group 1999</a>; <a href="./references#CD012721-bbs2-0398" title="PackerM , Poole-WilsonPA , ArmstrongPW , ClelandJG , HorowitzJD , MassieBM , et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation1999;100(23):2312-8.">Packer 1999</a>; <a href="./references#CD012721-bbs2-0400" title="PackerM , FowlerMB , RoeckerEB , CoatsAJS , Katus HugoA , KrumH , et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation2002;106(17):2194-9.">Packer 2002</a>; <a href="./references#CD012721-bbs2-0399" title="PackerM , CoatsAJ , FowlerMB , KatusHA , KrumH , MohacsiP , et al. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine2001;344(22):1651-8.">Packer 2001</a>; <a href="./references#CD012721-bbs2-0402" title="Pitt Bertram, Zannad Faiez, Remme WillemJ , Cody Robert, Castaigne Alain, Perez Alfonso, et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine1999;341(10):709-17.">Pitt 1999</a>; <a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>; <a href="./references#CD012721-bbs2-0414" title="SOLVD Investigators, YusufS , PittB , DavisCE , HoodWB , CohnJN . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine1991;325(5):293-302.">SOLVD Investigators 1991</a>; <a href="./references#CD012721-bbs2-0415" title="SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine1992;1992(327):685-91.">SOLVD Investigators 1992</a>; <a href="./references#CD012721-bbs2-0422" title="ZannadF , McMurrayJJV , KrumH , vanVeldhuisenDJ , SwedbergK , ShiH , et al. Eplerenone in patients with systolic heart failure and mild symptoms. New England Journal of Medicine2011;364(1):11-21.">Zannad 2011</a>). Angiotensin receptor antagonists (ARBs) are recommended as an alternative to ACEIs in patients with intolerance to these agents or, in combination with ACEIs, for patients treated with BBs who are unable to tolerate MRAs (<a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). Angiotensin receptor neprilysin inhibitors (ARNIs) are recommended as an alternative to ACEIs, with superior efficacy in people with HFrEF who remain symptomatic despite optimal therapy (<a href="./references#CD012721-bbs2-0395" title="McMurrayJJ , PackerM , DesaiAS , GongJ , LefkowitzMP , RizkalaAR , et al, PARADIGM-HF Investigators and Committees. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine2014;371(11):993-1004.">McMurray 2014</a>). Although neurohumoral activation is observed in HFpEF (<a href="./references#CD012721-bbs2-0390" title="HoggK , McMurrayJ . Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases2005;47(6):357-66.">Hogg 2005</a>), comparatively fewer clinical trials of neurohumoral inhibitor therapies have been performed in this population. The existing evidence from individual trials of BBs, MRAs, ACEIs, ARBs or MRAs in people with HFpEF does not support a reduction in mortality with these treatments (<a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). However, limited evidence indicates that candesartan (an ARB) (<a href="./references#CD012721-bbs2-0421" title="YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJV , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81.">Yusuf 2003</a>) and spironolactone (an MRA) (<a href="./references#CD012721-bbs2-0403" title="PittB , PfefferMA , AssmannSF , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92.">Pitt 2014</a>) may be effective in reducing numbers of people hospitalised with HF. </p> <p>This review sought to determine whether neurohumoral inhibition with therapies that improve mortality and morbidity in those with HFrEF (BBs, MRAs, ACEIs, ARBs, and ARNIs) have similar benefit in people with HFpEF. </p> </section> <section id="CD012721-sec-0012"> <h3 class="title" id="CD012721-sec-0012">How the intervention might work</h3> <p>In people with HFpEF, inadequate cardiac function triggers compensatory neurohumoral responses similar to those observed in HFrEF (<a href="./references#CD012721-bbs2-0390" title="HoggK , McMurrayJ . Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases2005;47(6):357-66.">Hogg 2005</a>). Activation of the renin‐angiotensin aldosterone system (RAAS) and increased tone of the sympathetic nervous system may be adaptive in the short term; however, chronic activation is likely to be detrimental. Pre‐clinical disease models of HFpEF suggest that RAAS activation leads to maladaptive hypertrophy and fibrosis (<a href="./references#CD012721-bbs2-0410" title="SharmaK , KassDA . Heart failure with preserved ejection fraction mechanisms, clinical features, and therapies. Circulation Research2014;115:79-96.">Sharma 2014</a>). ACEIs, ARBs or MRAs inhibit components of the RAAS system to counter the over‐activation that occurs in people with HF. ARNIs combine inhibition of RAAS with an ARB (valsartan) with augmentation of the natriuretic peptide system by inhibition of neprilysin (sacubitril). Neprilysin is a neutral endopeptidase that degrades a number of endogenous vasoactive peptides serving to counteract some of the effects of RAAS activation (<a href="./references#CD012721-bbs2-0395" title="McMurrayJJ , PackerM , DesaiAS , GongJ , LefkowitzMP , RizkalaAR , et al, PARADIGM-HF Investigators and Committees. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine2014;371(11):993-1004.">McMurray 2014</a>). The beneficial effects of BB therapy in people with HFrEF are thought to be mediated reducing the downstream effects associated with increased tone of the sympathetic nervous system, including increased heart rate, adverse myocardial energetics, and stimulation of RAAS (<a href="./references#CD012721-bbs2-0409" title="Sackner-BernsteinJD , ManciniDM . Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA1995;274(18):1462-7.">Sackner‐Bernstein 1995</a>). These mechanisms may also be important in HFpEF and the effect of BBs to increase diastolic filling time may be particularly important (<a href="./references#CD012721-bbs2-0410" title="SharmaK , KassDA . Heart failure with preserved ejection fraction mechanisms, clinical features, and therapies. Circulation Research2014;115:79-96.">Sharma 2014</a>); however, it is also possible that BB treatment may have adverse effects in this patient population. The population of people with HFpEF is heterogeneous, both with respect to disease aetiology and comorbidity. However, it is possible that neurohumoral activation represents a common pathophysiological mechanism that could be successfully targeted to improve clinical outcomes in people with heart failure across the spectrum of LVEF. </p> </section> <section id="CD012721-sec-0013"> <h3 class="title" id="CD012721-sec-0013">Why it is important to do this review</h3> <p>There is uncertainty as to whether BBs or RAAS inhibitors are effective at reducing mortality and heart failure hospitalisation and improving quality of life in people with HFpEF. Guidelines offer no specific treatment recommendations regarding the use of these therapies beyond the management of comorbidities, aside from a weak recommendation that ARBs and MRA might be considered to reduce hospitalisations (<a href="./references#CD012721-bbs2-0420" title="YancyCW , JessupM , BozkurtB , ButlerJ , Casey JrDE , ColvinMM , et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136(6):e137-61.">Yancy 2017</a>). The European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure highlight a gap in the evidence for the effects of ARNIs and BBs in the treatment of HFpEF (<a href="./references#CD012721-bbs2-0404" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal2016;37(27):2129-200.">Ponikowski 2016</a>). </p> <p>A recent systematic review and meta‐analysis of pharmacotherapy in HFpEF included BBs and RAAS inhibitors (ACEIs, ARBs and MRAs) and suggested a reduction in cardiovascular and all‐cause mortality with BB therapy (<a href="./references#CD012721-bbs2-0423" title="ZhengSL , ChanFT , NabeebaccusAA , ShahAM , McDonaghT , OkonkoDO , et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart2018;104:407-15.">Zheng 2018</a>). An updated review with a more comprehensive search strategy is needed to inform new guideline recommendations and to inform the conduct of further clinical trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012721-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012721-sec-0014"></div> <p>To assess the effects of BBs, ACEIs, ARBs, ARNIs, and MRAs in people with HFpEF.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012721-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012721-sec-0015"></div> <section id="CD012721-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012721-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with parallel group design. We excluded cross‐over trials because we considered these to be inappropriate for our review question due to the progressive nature of HF. </p> <p>Studies published in full‐text or as abstracts, or available only as unpublished data, were eligible for inclusion. </p> </section> <section id="CD012721-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies with adult participants (aged ≥ 18 years) with HFpEF defined by a LVEF greater than 40%. We recognised that there was likely to be significant heterogeneity among study populations, relating to the disease definition, and we summarise this narratively in the <a href="#CD012721-sec-0096">Discussion</a>. In relation to ejection fraction, we contacted study authors to obtain data on the subgroup of interest for studies with mixed populations. </p> </section> <section id="CD012721-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We performed separate meta‐analyses of studies that compared BBs, MRAs, ACEIs, ARBs or ARNIs, in addition to standard care. For BBs, MRAs, ACEIs and ARBs, the comparator was with placebo or no‐treatment control. For ARNIs, we meta‐analysed studies that compared sacubitril‐valsartan with valsartan, an ARB. </p> </section> <section id="CD012721-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Reporting one of more of the listed outcomes in the trial was not an inclusion criterion for the review. We assessed outcomes at the longest reported follow‐up. </p> <section id="CD012721-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012721-list-0001"> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Heart failure hospitalisation (number of participants with at least one hospitalisation, analysed as risk ratios (RR), and time to first event, analysed as hazard ratios (HR)). </p> </li> <li> <p>Hyperkalaemia.</p> </li> </ol> </p> </section> <section id="CD012721-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012721-list-0002"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Quality of life (measured with either the 'Minnesota Living with Heart Failure Questionnaire' (MLHFQ) or the 'Kansas City Cardiomyopathy Questionnaire' (KCCQ)). </p> </li> <li> <p>Withdrawal due to adverse event (hypotension, hyperkalaemia or renal impairment).</p> </li> </ol> </p> </section> </section> </section> <section id="CD012721-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012721-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We updated the systematic searches of the following bibliographic databases on 14 May 2020: </p> <p> <ol id="CD012721-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (Issue 5 of 12, 2020); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 12 May 2020); and </p> </li> <li> <p>Embase and Embase Classic (Ovid, 1947 to 13 May 2020) .</p> </li> </ol> </p> <p>The search strategies used in 2017 are included in <a href="./appendices#CD012721-sec-0113">Appendix 1</a> and those used in 2020 are in <a href="./appendices#CD012721-sec-0119">Appendix 2</a>. We applied the Cochrane sensitivity‐maximising RCT filter (<a href="./references#CD012721-bbs2-0393" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, Noel-StorrA , et al. Chapter 4: Searching for and selecting studies. In: HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editors(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook..">Lefebvre 2019</a>) to MEDLINE (Ovid). For Embase, the RCT filter with the best optimisation of sensitivity and specificity was applied, as in the previous search. (<a href="./references#CD012721-bbs2-0418" title="WongSS , WilczynskiNL , HaynesRB . Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. Journal of the Medical Library Association2006;94(1):41-7.">Wong 2006</a>). </p> <p>We did not impose any restriction on language of publication.</p> </section> <section id="CD012721-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) for ongoing trials on 14 May 2020. We were unable to search the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) as it was unavailable at the time of searching. Search terms for the trials registers are also listed in <a href="./appendices#CD012721-sec-0113">Appendix 1</a> (from 2017) and <a href="./appendices#CD012721-sec-0119">Appendix 2</a> (from 2020). </p> <p>We checked all primary references of included studies and systematic reviews for additional references. For studies identified as eligible from clinical trial register records, we searched for associated publications on PubMed and in recent conference presentations. </p> <p>We contacted study authors to clarify details or obtain additional information not included in the published reports. </p> </section> </section> <section id="CD012721-sec-0026"> <h3 class="title" id="CD012721-sec-0026">Data collection and analysis</h3> <section id="CD012721-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KM and NM) independently screened titles and abstracts of all records identified in our search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. In the event of disagreement, a third review author was asked to arbitrate (TL). We then retrieved the full‐text study reports for records identified as eligible, potentially eligible or unclear. Two review authors (KM and NM) independently screened the full‐text articles and identified studies for inclusion. We recorded reasons for exclusion of ineligible studies. We resolved any disagreement by consensus or consulted a third review author (TL). We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report is the unit of interest in the review. We recorded the selection process and completed a PRISMA flow diagram (<a href="#CD012721-fig-0001">Figure 1</a>) and the <a href="./references#CD012721-sec-0134" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD012721-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012721-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012721-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form to record study characteristics and outcome data from included studies, which had been piloted on two studies in the review (<a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). Some modifications were made after the pilot phase. Two review authors (NM and TL for <a href="./references#CD012721-bbs2-0425" title="MartinN , ManoharanK , ThomasJ , DaviesC , LumbersRT . Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012721. [DOI: 10.1002/14651858.CD012721.pub2]">Martin 2018</a>, and NM and KM for this update) extracted study characteristics from included studies as follows: </p> <p> <ol id="CD012721-list-0004"> <li> <p>Methods: study design, duration of follow‐up, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and start/end date of enrolment. </p> </li> <li> <p>Participants: number randomised/withdrawn/lost to follow‐up/analysed, mean age/age range, percent male, inclusion criteria, exclusion criteria, systolic blood pressure, heart rate, body mass index, serum creatinine, B‐type natriuretic peptide, NT pro B‐type natriuretic peptide, LVEF, New York Heart Association (NYHA) class, comorbidity (hypertension, diabetes, atrial fibrillation, hospitalisation for HF, coronary heart disease, stroke, medications at baseline). </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications (diuretic, digoxin, BBs, ACEIs, ARBs, MRAs). </p> </li> <li> <p>Outcomes: planned and reported.</p> </li> <li> <p>Notes: sources of funding, and notable conflicts of interest of trial authors.</p> </li> </ol> </p> <p>Two review authors (NM and TL for <a href="./references#CD012721-bbs2-0425" title="MartinN , ManoharanK , ThomasJ , DaviesC , LumbersRT . Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012721. [DOI: 10.1002/14651858.CD012721.pub2]">Martin 2018</a> and NM and KM for this update) independently extracted outcome data from included studies. Disagreements were resolved by consensus. One review author (NM) transferred data into the Review Manager 5 (<a href="./references#CD012721-bbs2-0406" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.">RevMan 2014</a>) file. One review author (TL) double‐checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction sheet. </p> </section> <section id="CD012721-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NM and TL) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012721-bbs2-0388" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011.">Higgins 2011</a>). Disagreements were resolved by consensus. We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD012721-list-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We judged each potential source of bias as high, low or unclear and provided quotes from study reports together with justification for our judgment in the 'Risk of bias' table. We summarised the 'Risk of bias' judgements across different studies for each of the domains listed. Where information on risk of bias related to unpublished data or correspondence with a triallist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects in the pooled analysis, we accounted for risk of bias for the studies that contributed to each outcome tested. </p> <section id="CD012721-sec-0030"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol and reported protocol deviations in the <a href="#CD012721-sec-0131">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD012721-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as RR with 95% confidence intervals (CIs), and continuous data as mean difference (MD) or standardized mean difference (SMD), with 95% CIs. In addition, wherever possible, we performed a pooled analysis of outcomes reported as HRs. We used SMD for one analysis when combining quality of life data reported for two different scales and followed Cohen's effect sizes of 0.2 representing a small effect, 0.5 a moderate effect and 0.8 a large effect (<a href="./references#CD012721-bbs2-0378" title="CohenJ . Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale (NJ): Lawrence Erlbaum Associates, Inc., 1988.">Cohen 1988</a>). We entered data presented as a scale with a consistent direction of effect. </p> </section> <section id="CD012721-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We included one three‐arm trial (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>). Because two intervention arms contributed to two separate comparisons, no unit of analysis issue arose. </p> </section> <section id="CD012721-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and where possible, obtain missing numerical outcome data. </p> </section> <section id="CD012721-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to measure heterogeneity among the trials in each analysis. We considered possible causes in cases of substantial heterogeneity (I² = 50% to 100%). </p> </section> <section id="CD012721-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We pooled fewer than 10 trials for each comparison. Therefore, we did not examine funnel plots to explore possible small‐study biases for the primary outcomes. We plan to do so, should a sufficient number of trials become available in future updates of this review. </p> </section> <section id="CD012721-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only where this was meaningful, that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. We used a fixed‐effect model in the absence of substantial heterogeneity (I² &lt; 50%) and a random‐effects model when unexplained substantial heterogeneity was present (I² ≥ 50%). We applied a random‐effects model for quality of life analyses for MRAs to account the high heterogeneity observed for the KCCQ (<a href="./references#CD012721-fig-0015" title="">Analysis 2.7</a>; I² = 86%) and to permit a combined analysis with outcome data from the MLHFQ (<a href="./references#CD012721-fig-0014" title="">Analysis 2.6</a>; I² = 50%). </p> <p>We considered two relevant quality of life scales: the MLHFQ or KCCQ. The MLHFQ score has a range from 0 to 105, lower scores indicate better quality of life. The KCCQ score has a range from 0 to 100, higher scores indicate better quality of life. To account for the difference in the direction of the scale of the KCCQ, the mean values were multiplied by ‐1 (<i>Cochrane Handbook</i> <i>for Systematic Reviews of Interventions</i>, section 9.2.3.2, <a href="./references#CD012721-bbs2-0381" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: HigginsJP , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.">Deeks 2011</a>). For the purpose of interpretation, we considered a five point difference in score as clinically significant for the MLHFQ (<a href="./references#CD012721-bbs2-0405" title="Rector TS , Tschumperlin LK , Kubo SH , Bank AJ , Francis GS , McDonald KM , et al. Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. Journal of Cardiac Failure1995;1(3):201-6.">Rector 1995</a>) and KCCQ (<a href="./references#CD012721-bbs2-0416" title="SpertusJ , PetersonE , ConardMW , HeidenreichPA , KrumholzHM , JonesP , et al. Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. American Heart Journal2005;150:707-15.">Spertus 2005</a>). </p> </section> <section id="CD012721-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses.</p> <p> <ol id="CD012721-list-0006"> <li> <p>Age. The potential effect of age as an effect modifier of RAAS inhibition is not well described. We planned to explore outcomes for subgroups defined by age as less than 70 years and 70 years and over. This is based on the median age of participants in two major HFpEF trials: the <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> median age was 68.7 years and the <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> mean age was 72 years. </p> </li> <li> <p>Sex.</p> </li> <li> <p>HFmrEF LVEF 40% to 49% and preserved LVEF equal to or greater than 50%.</p> </li> <li> <p>Length of follow‐up less than 12 months and equal to or greater than 12 months.</p> </li> </ol> </p> <p>We were unable to perform subgroup analyses, due to insufficient data (<a href="./references#CD012721-bbs2-0382" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: analysing data and undertaking meta-analyses. In: HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editors(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> <p>If we had been able to conduct subgroup analyses, we had planned to use the outcomes of cardiovascular mortality and hospitalisation for heart failure and the formal test for subgroup interactions in Review Manager 5 (<a href="./references#CD012721-bbs2-0406" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD012721-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis for risk of bias by performing a pooled analysis that included only studies with a low risk of bias (where at least four of the six domains for bias assessment were judged to be low risk, and no domain was at high risk of bias). </p> </section> <section id="CD012721-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created 'Summary of findings' tables for each of our five interventions and included the following outcomes: cardiovascular mortality, heart failure hospitalisation, all‐cause mortality, quality of life (when available MLHFQ, alternatively KCCQ) and hyperkalaemia<i>.</i> We used the five GRADE considerations (study limitations, inconsistencies, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the studies which contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012721-bbs2-0388" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011.">Higgins 2011</a>) using GRADEpro software (<a href="./references#CD012721-bbs2-0387" title="GRADEpro GDT. Version accessed prior to 12 February 2018. Hamilton, ON: McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). Four review authors assessed the certainty of evidence (TL, NM, KM, CD). We used footnotes to document our justification for decisions to downgrade the certainty of evidence. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012721-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012721-sec-0040"></div> <section id="CD012721-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD012721-sec-0042"> <h4 class="title">Results of the search</h4> <p>We previously included 37 studies, reported in 207 references (<a href="./references#CD012721-bbs2-0425" title="MartinN , ManoharanK , ThomasJ , DaviesC , LumbersRT . Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012721. [DOI: 10.1002/14651858.CD012721.pub2]">Martin 2018</a>). For this update, the database searches identified 1223 new reports, and a search of ClinicalTrials.gov retrieved 251 additional records. After de‐duplication, we screened 1130 records based on the titles and abstracts. Of these, 1038 did not meet the inclusion criteria and were excluded. The remaining 92 records were assessed for eligibility in full‐text and 24 references were included. We identified eight additional references for four previously included studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>). We included four new studies in this updated review (<a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>), reported in 17 references. <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> had previously been identified as an ongoing study. We thus now include a total of 41 studies in this review </p> <p>We identified 11 new ongoing studies, bringing the total of ongoing studies to 13. Three new studies were added to the category of '<a href="./references#CD012721-bbs1-0003" title="">Studies awaiting classification</a>' (<a href="./references#CD012721-bbs2-0355" title="BotoniF , Poole-WilsonPPW , RibeiroALP , GuedesVC , OliveiraBMR , TeixeiraMM , et al. Assessment of the Quality of Life (SF36) after optimized cardiovascular therapy in Chagas cardiomyopathy. European Journal of Heart Failure Supplement2010;9:S108. ">Botoni 2010</a>; <a href="./references#CD012721-bbs2-0360" title="PER-010-15. A multicenter, randomized, double blind, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA class II-IV) with preserved ejection fraction. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?ver=EN&amp;numEc=010-15 (registration date 9 June 2015). ">PER‐010‐15</a>; <a href="./references#CD012721-bbs2-0361" title="Przewlocka-KosmalaM , KosmalaW , MarwickTWH . Effect of aldosterone antagonism on active and passive determinants of LV diastolic filling and exercise intolerance in heart faillure with preserved ejection fraction. European Heart Journal Supplements2017;18(Suppl 3):iii223. ">Przewlocka‐Kosmala 2017</a>) bringing the total to nine studies in this category. </p> </section> <section id="CD012721-sec-0043"> <h4 class="title">Included studies</h4> <p>We included 41 studies (234 reports) that involved a total of 26,059 participants.</p> <section id="CD012721-sec-0044"> <h5 class="title">BBs</h5> <p>We included 10 studies (3087 participants) that investigated BBs for HFpEF. Of these, five studies compared BBs versus placebo (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>) and five versus usual care (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). Four studies investigated carvedilol: <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a> (up to 50 mg daily), <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> (up to 10 mg twice daily), <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a> (up to 25 mg twice daily or 50 mg twice daily in people weighing over 85 kg), <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a> (up to 20 mg daily). Two studies used nebivolol: <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> (up to 10 mg daily) and <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> (up to 10 mg daily). One study used propranolol: <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a> (30 mg, three times daily); and two studies investigated metoprolol succinate: <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a> (up to 100 mg daily). <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a> investigated bisoprolol (up to 10 mg daily). </p> <p>Numbers of participants randomised ranged from 40 (<a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>) to 643 (<a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>). </p> <p>Four were multicentre studies. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> was conducted across 12 centres in eight countries in Europe; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> was assumed to have taken place in Japan; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> took place in 11 countries (Czech Republic, France, Germany, Hungary, Italy, Netherlands, Romania, Spain, Switzerland, UK and Ukraine), and <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a> took place in 12 centres in Sweden. <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a> and <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a> were each conducted in one centre in India. <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>, <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a> and <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a> did not report numbers of centres or countries, but we assumed that <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a> likely took place in Armenia. <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a> was a single centre trial in Japan. </p> <p>Three studies did not report LVEF of the included participants at baseline (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>). Six studies reported LVEF at baseline with a mean ranging from 56% to 63% (<a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> included participants with a "clinical history of chronic HF with at least 1 of the following features: documented hospital admission within the previous 12 months with a discharge diagnosis of congestive HF or documented LVEF ≤ 35% within the previous 6 months". The <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> study reported a subgroup of participants with LVEF greater than 40% and these outcome data were used in our analysis (643 participants). </p> <p>Most participants were NYHA class II (51% to 78%). <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a> did not report participants' NYHA class at baseline. Participants' mean age ranged from 30 years to 81 years; six studies reported mean age less than 70 years (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>) and four reported mean age above 70 years (<a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). </p> <p>Three studies were funded by industry (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>); two studies were funded by not‐for‐profit organisations (<a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>); and five did not report sources of funding (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). </p> </section> <section id="CD012721-sec-0045"> <h5 class="title">MRAs</h5> <p>We included 13 studies that investigated MRAs for HFpEF. Of these, eight compared MRAs versus placebo (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) and five versus usual care (<a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0039" title="WangYC , YuCC , ChiuFC , TsaiCT , LaiLP , HwangJJ , et al. Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure. Circulation2010;122(2):P1059. ">Wang 2010</a>). Ten studies investigated spironolactone (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a> (initiated at 25 mg daily and up‐titrated to a maximum of 50 mg daily); <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a> (25 mg daily); <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a> (25 mg daily); <a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a> (25 mg daily, up‐titrated if tolerated to 50 mg daily); <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> (15 mg daily, increased to a maximum of 45 mg daily); <a href="./references#CD012721-bbs2-0039" title="WangYC , YuCC , ChiuFC , TsaiCT , LaiLP , HwangJJ , et al. Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure. Circulation2010;122(2):P1059. ">Wang 2010</a> (50 mg daily)). Two studies used eplerenone (<a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a> (25 mg daily to a maximum of 50 mg daily)). <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> investigated canrenone at a maximum dose of 50 mg daily. </p> <p>Numbers of participants randomised ranged from 28 (<a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>) to 3445 (<a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). Four were multicentre trials; <a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a> included 10 centres in Germany and Austria; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> was conducted in 46 centres in Italy; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a> had centres in Poland (the number is unclear but publication states "of each centre"); and <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> was conducted across 233 sites in six countries (Argentina, Brazil, Canada, Georgia, Russia, USA). Six studies were single‐centre trials; two in USA (<a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>), one in the UK (<a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>), one in Australia (<a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>) and one in Taiwan (<a href="./references#CD012721-bbs2-0039" title="WangYC , YuCC , ChiuFC , TsaiCT , LaiLP , HwangJJ , et al. Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure. Circulation2010;122(2):P1059. ">Wang 2010</a>); <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a> was a single‐centre trial but the country was unspecified. Three trials did not report on numbers of centres or countries (<a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). </p> <p>Two studies (<a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>) did not report participants' LVEF at baseline. <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> had a mean LVEF at baseline of 39.9% (intervention) and 39.7% (control) for the overall included participants (N = 467). However, we obtained outcome data for the subgroup of participants with LVEF greater than 40% (N = 225). The LVEF in the remaining seven studies ranged from 54% to 72%. </p> <p>In one study, most participants were NYHA class I (<a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>, 61%). Most participants in five studies were NYHA class II (52% to 88%; <a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). Most participants in two studies were NYHA class III (58% to 64%; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). Three studies did not report NYHA class for participants eligible for inclusion in our review (<a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>). <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a> reported that most participants in the intervention arm were NYHA class III (57.1%) and NYHA class I (75%) in the control arm. </p> <p>Participants' mean age ranged from 54.5 years to 80 years; seven studies included participants whose mean age was less than 70 years (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). In five studies, participants' mean age was over 70 years (<a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). </p> <p><a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> was industry funded; seven studies were funded by not‐for‐profit organisations (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). Five studies did not report sources of funding (<a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0039" title="WangYC , YuCC , ChiuFC , TsaiCT , LaiLP , HwangJJ , et al. Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure. Circulation2010;122(2):P1059. ">Wang 2010</a>). </p> </section> <section id="CD012721-sec-0046"> <h5 class="title">ACEIs</h5> <p>We included eight studies that investigated ACEIs for HFpEF. Of these, three compared ACEIs with placebo (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>), and five versus usual care (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>; <a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>). Two studies investigated enalapril (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a> up to 20 mg daily; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a> up to 10 mg daily). <a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a> investigated benazepril (up to 40 mg daily). Two studies investigated perindopril (<a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> up to 4 mg daily; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>, up to 10 mg). <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a> investigated ramipril in one of two active arms (maximum of 10 mg daily). Two studies investigated quinapril (<a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>, dose not reported; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>, up to 40 mg daily). </p> <p>Numbers of participants randomised ranged from 21 (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>) to 850 (<a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>). Two studies were reportedly multicentre trials (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>). <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a> did not report details on the number of centres. <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> was conducted at 53 centres in Bulgaria (3), Czech Republic (5), Hungary (10), Ireland (1), Poland (26), Russia (1), Slovakia (2), and the UK (5). <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a> took place at one hospital in the UK and <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a> was conducted in Turkey. The countries or number of centres were not reported in four studies (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>; <a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>). </p> <p>The mean LVEF of the included participants at baseline was not reported by two studies (<a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>). LVEF ranged from 61% to 69% in five studies (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>; <a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>). Most participants were classified in NYHA class II in four studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) and in NYHA class III in one study (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>). Two studies did not report participants' NYHA class at baseline (<a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>). </p> <p>Participants' mean age ranged from 70 years to 82 years with all studies equal to or over a mean age of 70 years. </p> <p>Four studies did not report funding sources (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>; <a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>). Three studies were industry‐funded (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) and one study was funded by a not‐for profit organisation (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>). </p> </section> <section id="CD012721-sec-0047"> <h5 class="title">ARBs</h5> <p>We included eight studies that investigated ARBs for HFpEF. Of these, five compared ARBs versus placebo (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) and three compared ARBs versus usual care (<a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>). Four studies investigated candesartan (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a> (up to 32 mg daily), <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a> (8 mg to 12 mg daily)). Two studies investigated irbesartan (one of the two active treatment arms in <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a> (up to 75 mg daily), <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a> (up to 300 mg)). <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a> investigated valsartan (80 mg daily). <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a> investigated olmesartan (up to 40 mg daily). </p> <p>Numbers of participants randomised ranged from 22 (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>) to 4128 (<a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>). Seven were multicentre trials: <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a> was conducted at eight centres in Germany; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a> at 70 centres in Italy; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a> was conducted at 618 centres in 26 countries; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a> involved 293 centres in 25 countries; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a> was conducted at five centres each in Germany and the UK; and <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a> was conducted at 17 centres in Japan. <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a> was reported to be a multicentre trial but no details were provided on numbers of centres or countries. <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a> was reported to be a single‐centre trial in Japan. </p> <p>The mean LVEF of the included participants at baseline was not reported by <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a> and ranged from 49% to 72% in seven studies (<a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>). Most participants were assessed as NYHA class II at baseline in five studies (<a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>); NYHA class III in <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; and was not reported by two studies (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>). </p> <p>Participants' mean age ranged from 61 years to 75 years. Mean age was below 70 years in six studies (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>) and over 70 years in two studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>). </p> <p>Six studies were funded by industry (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>). <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a> was funded by a not‐for‐profit organisation. <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a> did not report the source of funding. </p> </section> <section id="CD012721-sec-0048"> <h5 class="title">ARNIs</h5> <p>For this update, we elected to include three studies comparing an ARNI (sacubitril‐valsartan) with an ARB (valsartan) (<a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a> and <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>), and one study comparing an ARNI (sacubitril‐valsartan) with individualised medical therapy whereby the comparator was specified according to the RAAS treatment status of patients at study enrolment; patients treated with ACEI at enrolment received LCZ696 or enalapril, those treated with ARB received LCZ696 or valsartan, and those without prior treatment with RAAS inhibition received LCZ696 or matching placebo) (<a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a>). </p> <p>Administration of ARBs or ACEIs in combination with sacubitril‐valsartan is contraindicated due to safety concerns. Therefore, the investigators specified the active comparator of valsartan, given that many patient with HFpEF receive ARB or ACEI treatment for hypertension (<a href="./references#CD012721-bbs2-0411" title="SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 inheart failure with preserved ejection fraction: a phase 2double-blind randomised controlled trial. Lancet2012;380:1387-95.">Solomon 2012</a>). Since both treatment arms received valsartan, these studies isolate the effects of neprilysin. However, this can only be safely administered in combination with an ARB (i.e. the ARNI class of therapeutics). </p> <p>Number of participants randomised ranged from 308 (<a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>) to 4822 participants (<a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>). <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> was a multicentre trial across 848 centres in 43 countries and <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a> had 65 centres and 13 countries. The mean LVEF was 56 to 58% across the three trials. Most participants in these trials were assessed as NYHA class II at baseline. Participants' mean age ranged from 71 to 73 years of age. Novartis funded the three studies. </p> <p>PERSPECTIVE (<a href="./references#CD012721-bbs2-0367" title="EUCTR2016-001254-17. A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (PERSPECTIVE). www.clinicaltrialsregister.eu/ctr-search/trial/2016-001254-17/GB (first entered 11 August 2016). ">EUCTR2016‐001254‐17</a>) is an ongoing RCT to examine the effect of LCZ696 compared to valsartan on cognitive outcomes in participants with HFpEF, defined as LVEF greater than 40%. </p> </section> </section> <section id="CD012721-sec-0049"> <h4 class="title">Excluded studies</h4> <p>We previously excluded 303 studies (324 references) based on full‐text assessment (<a href="./references#CD012721-bbs2-0425" title="MartinN , ManoharanK , ThomasJ , DaviesC , LumbersRT . Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews2018, Issue 6. Art. No: CD012721. [DOI: 10.1002/14651858.CD012721.pub2]">Martin 2018</a>). Details for the reasons for exclusion are provided in the <a href="./references#CD012721-sec-0134" title="">Characteristics of excluded studies</a> table. In this update, we have excluded 52 studies (54 references) and added these to the list for exclusions below. We referenced in the review only those that most closely missed the inclusion criteria (four references). In summary, we made exclusions based on the following considerations: </p> <p> <ul id="CD012721-list-0007"> <li> <p>population does not meet protocol: n = 118;</p> </li> <li> <p>wrong intervention: n = 8;</p> </li> <li> <p>wrong comparator: n = 23;</p> </li> <li> <p>wrong study design: n = 125;</p> </li> <li> <p>subgroup of interest but no response to our enquiry for data: n = 8;</p> </li> <li> <p>subgroup not of interest: n = 36;</p> </li> <li> <p>unclear eligibility and no response to our enquiry for details: n = 12;</p> </li> <li> <p>unclear eligibility and no current contact details: n = 15;</p> </li> <li> <p>completed status in trial registry record but no published results and no response to our enquiry for data: n = 1; </p> </li> <li> <p>missing data and response that no details can be provided: n = 6;</p> </li> <li> <p>retraction: n = 1; and</p> </li> <li> <p>did not take place as planned: n = 2.</p> </li> </ul> </p> <section id="CD012721-sec-0050"> <h5 class="title">Studies awaiting classification</h5> <p>We identified nine studies that are awaiting classification (<a href="./references#CD012721-bbs2-0354" title="Anonymous. Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction. MMW Fortschritte der Medizin2003;145(44):42-3. ">Anonymous 2003d</a>; <a href="./references#CD012721-bbs2-0355" title="BotoniF , Poole-WilsonPPW , RibeiroALP , GuedesVC , OliveiraBMR , TeixeiraMM , et al. Assessment of the Quality of Life (SF36) after optimized cardiovascular therapy in Chagas cardiomyopathy. European Journal of Heart Failure Supplement2010;9:S108. ">Botoni 2010</a>; <a href="./references#CD012721-bbs2-0356" title="DielievskaVY . The effect of aldosterone receptor blockade in diastolic heart failure in patients with arterial hypertension combined with chronic obstructive pulmonary disease. General Medicine2015;17(3):3-7. ">Dielievska 2015</a>; <a href="./references#CD012721-bbs2-0357" title="EUCTR2005-001306-87. Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT#P (first entered 2 February 2007). ">EUCTR2005‐001306‐87</a>; <a href="./references#CD012721-bbs2-0358" title="EUCTR2005-002109-22. Comparative effects of telmisartan and candesartan on glucose metabolism in patients with chronic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2005-002109-22/AT (first entered 27 October 2005). ">EUCTR2005‐002109‐22</a><a href="./references#CD012721-bbs2-0359" title="MetraM , NodariS , BordonaliT , CagnazziE , BoldiE , Dei CasL . ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction. Cardiologia1999;44(Suppl 1):53-8. ">Metra 1999</a>; <a href="./references#CD012721-bbs2-0360" title="PER-010-15. A multicenter, randomized, double blind, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA class II-IV) with preserved ejection fraction. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevo.asp?ver=EN&amp;numEc=010-15 (registration date 9 June 2015). ">PER‐010‐15</a>; <a href="./references#CD012721-bbs2-0361" title="Przewlocka-KosmalaM , KosmalaW , MarwickTWH . Effect of aldosterone antagonism on active and passive determinants of LV diastolic filling and exercise intolerance in heart faillure with preserved ejection fraction. European Heart Journal Supplements2017;18(Suppl 3):iii223. ">Przewlocka‐Kosmala 2017</a>; <a href="./references#CD012721-bbs2-0362" title="RapezziC , PeruginiE , AmatiS , BranziA . Beta blockers and calcium antagonists in diastolic dysfunction. Cardiologia1999;44(Suppl 1):61-4. ">Rapezzi 1999</a>. See <a href="./references#CD012721-sec-0135" title="">Characteristics of studies awaiting classification</a>. We are waiting to retrieve the full‐text (n = 4), await responses from translators (n = 3) and await response from the triallists to clarify eligibility (n = 2). </p> </section> <section id="CD012721-sec-0051"> <h5 class="title">Ongoing studies</h5> <p>From the previously identified ongoing studies, two have now been included (<a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a>). We identified 11 new ongoing studies, bringing the current total to 13 ongoing studies (<a href="./references#CD012721-sec-0136" title="">Characteristics of ongoing studies</a>). </p> </section> </section> </section> <section id="CD012721-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessments are detailed in the <a href="./references#CD012721-sec-0133" title="">Characteristics of included studies</a> tables. We summarised them in the text below and in <a href="#CD012721-fig-0002">Figure 2</a> and <a href="#CD012721-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012721-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012721-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012721-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012721-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012721-sec-0053"> <h4 class="title">Allocation</h4> <p>Twelve studies reported random sequence methods and were rated as being at low risk of bias (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). We assessed 28 studies to be at unclear risk of bias for this domain because no information was provided in study reports. One study was assessed as high risk of bias in this domain as it randomised participants on the basis of admission sequence (<a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>). </p> <p>Twelve studies used a method for allocation concealment that was judged to be at low risk of bias (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). We assessed 29 studies to be at unclear risk of bias for this domain because no information was provided in study reports. </p> </section> <section id="CD012721-sec-0054"> <h4 class="title">Blinding</h4> <p>We assessed 22 studies to be at low risk of bias regarding blinding of participants and personnel (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>). Six studies were open‐label designs and therefore were judged to be at high risk of bias for this domain (<a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>). The remaining 13 studies were assessed at unclear risk of bias because no information was provided. </p> <p>Detection bias was judged to be at low risk in 18 studies (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). One study was judged to be at high risk of detection bias as outcome assessors were not blinded (<a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>). The remaining 22 studies did not provide information and were judged to be at unclear risk of detection bias. </p> </section> <section id="CD012721-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias was judged to be at low risk in 14 studies (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>). We judged <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a> to be at high risk of bias for this domain because the study report did not indicate if losses to follow‐up or withdrawals occurred. <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a> (unclear reporting of withdrawals) and <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a> (completed case analysis with uneven drop‐out in treatment arms) were also judged to be at high risk of bias. All 24 remaining studies were assessed to be at unclear risk of bias for attrition bias as no information was reported to allow judgement. </p> </section> <section id="CD012721-sec-0056"> <h4 class="title">Selective reporting</h4> <p>We assessed 12 studies to be at low risk of reporting bias (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). These 12 studies reported planned outcomes in either published protocols or clinical trial registers before enrolment started. We were unable to assess reporting bias in 29 studies either because no information was available in the form of protocols or clinical trial registry entries, or they were published/entered after enrolment was completed. </p> </section> <section id="CD012721-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>We judged 20 studies to be at low risk of other bias (mainly based on providing details on funding and declaring any conflict of interest by the authors) (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>). </p> <p>We judged six studies to be at high risk of other bias. <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a> was originally registered as an observational study and this detail was changed after completion of the trial, but before the results were published. Five studies (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) were published as conference abstracts only; withholding the full results from publication may present a form of bias. The remaining 15 studies were judged to be at unclear risk of bias. </p> </section> </section> <section id="CD012721-sec-0058"> <h3 class="title" id="CD012721-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD012721-tbl-0001"><b>Summary of findings 1</b> Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</a>; <a href="./full#CD012721-tbl-0002"><b>Summary of findings 2</b> Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</a>; <a href="./full#CD012721-tbl-0003"><b>Summary of findings 3</b> Angiotensin‐converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</a>; <a href="./full#CD012721-tbl-0004"><b>Summary of findings 4</b> Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</a>; <a href="./full#CD012721-tbl-0005"><b>Summary of findings 5</b> Angiotensin receptor neprilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction</a> </p> <section id="CD012721-sec-0059"> <h4 class="title">BBs versus placebo or no treatment</h4> <p>We included 10 studies involving a total of 3087 participants that assessed BBs versus placebo or no treatment. The main outcomes for this comparison are included in <a href="./full#CD012721-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012721-sec-0060"> <h5 class="title">Cardiovascular mortality</h5> <p>Six studies reported cardiovascular mortality (<a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). Three studies reported that no deaths occurred (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). We included three studies in the meta‐analysis (<a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>) (15% of participants in the intervention arm versus 19% in the control arm; RR 0.78, 95% CI 0.62 to 0.99; NNTB 25; 1046 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012721-fig-0004" title="">Analysis 1.1</a>). </p> <p><a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> reported cardiovascular mortality but with different numbers for events within the same table (Table 2 in the primary reference). We contacted the study authors to seek clarification but are yet to receive a response; we used the higher numbers in the analysis. </p> <p><a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> reported a hazard ratio (HR 0.80, 95% CI 0.49 to 1.32; 643 participants). </p> </section> <section id="CD012721-sec-0061"> <h5 class="title">Heart failure hospitalisation</h5> <p>We included five studies that reported heart failure hospitalisation (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> reported that no hospitalisation occurred due to HF. Data from four studies (<a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0031" title="ShuM , XiR , ZhangP , HeG , SongZ , ChiL , et al. Short-term and long-term effects of bisoprolol on chronic heart failure related to rheumatic heart disease and atrial fibrillation. Pharmacy and Therapeutics2005;30(7):400-7. ">Shu 2005</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>) contributed to the meta‐analysis (RR 0.73, 95% CI 0.47 to 1.13; 449 participants; I² = 22%; very low‐certainty evidence; <a href="./references#CD012721-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD012721-sec-0062"> <h5 class="title">Hyperkalaemia</h5> <p><a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> reported that one participant in the intervention group (N = 120) experienced hyperkalaemia but did not report on this outcome for the control group (very low‐certainty evidence). No further data were available from any other studies. </p> </section> <section id="CD012721-sec-0063"> <h5 class="title">All‐cause mortality</h5> <p>We included seven studies that reported all‐cause mortality (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). Of these, three studies reported that no deaths occurred (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>). We included data from four studies in the meta‐analysis (<a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>; <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>) (RR 0.82, 95% CI 0.67 to 1.00; 1105 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012721-fig-0006" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> reported all‐cause mortality but with different numbers for events within the same table (Table 2 in the primary reference). We contacted the study authors to seek clarification but are yet to receive a response. We used the higher number of deaths in the analysis. </p> <p><a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> reported a hazard ratio (HR 0.92, 95% CI 0.61 to 1.36; 643 participants). </p> </section> <section id="CD012721-sec-0064"> <h5 class="title">Quality of life</h5> <p>We included two studies that reported quality of life (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>). <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a> reported quality of life using SF‐36, which was not a scale we considered for our analysis. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> reported end scores for the MLHFQ total score and showed MD ‐1.00 between the treatment arms, favouring the intervention (95% CI ‐9.05 to 7.05; 93 participants; very low‐certainty evidence). </p> </section> <section id="CD012721-sec-0065"> <h5 class="title">Withdrawal due to adverse event</h5> <p>We included five studies that reported withdrawals due to adverse events (<a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a>; <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a>; <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a>). <a href="./references#CD012721-bbs2-0020" title="CTRI/2010/091/000438. Evaluation of efficacy and safety of metoprolol in patients having heart failure with normal ejection fraction: a randomised, double-blind, placebo-controlled trial [A clinical trial to study the efficacy and safety of metoprolol in heart failure with normal ejection fraction]. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1626 (registered on 19 May 2010). MittalN , ShafiqN , ReddyS , MalhotraS , KumariS , VarmaS . Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial. Perspectives in Clinical Research2017;8(3):124-31. ">Mittal 2017</a> and <a href="./references#CD012721-bbs2-0029" title="SahooD , KapoorA , SinhaA , KhannaR , KumarS , GargN , et al. Targeting the sympatho-adrenergic link in chronic rheumatic mitral regurgitation: assessing the role of oral beta-blockers. Cardiovascular Therapeutics2016;34(4):261-7. ">Sahoo 2016</a> reported no withdrawals due to adverse events. <a href="./references#CD012721-bbs2-0005" title="AronowWS , AhnC , KronzonI . Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction &gt; or = 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. American Journal of Cardiology1997;80(2):207-9. ">Aronow 1997</a> reported 11 withdrawals due to "worsening CHF [chronic heart failure] in 7 patients and hypotension in 4 patients" but did not provide this information by intervention arm. Only two studies (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>) contributed data for meta‐analysis (9% of participants in the intervention arm versus 0% in the control arm, RR 18.07, 95% CI 2.45 to 133.04; 338 participants; I² = 0%; <a href="./references#CD012721-fig-0008" title="">Analysis 1.5</a>; number needed to harm (NNTH) = 11). </p> </section> </section> <section id="CD012721-sec-0066"> <h4 class="title">MRAs versus placebo or no treatment</h4> <p>We included 13 studies (4459 participants) that assessed MRAs versus placebo or no treatment. The main outcomes for this comparison are included in <a href="./full#CD012721-tbl-0002">summary of findings Table 2</a>. The findings for this comparison were driven by one trial (<a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). Four trials (<a href="./references#CD012721-bbs2-0014" title="KarapyshVA , VatutinNT , ShevelokAN . Effects of spironolactone on the left ventricular hypertrophy in chronic heart failure with preserved ejection fraction. European Journal of Heart Failure2015;17:48. ">Karapysh 2015</a>; <a href="./references#CD012721-bbs2-0021" title="MottramPM , HaluskaB , LeanoR , CowleyD , StowasserM , MarwickTH . Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation2004;110:558-65. MottramPM , HaluskaBA , LeanoR , CowleyD , StowasserM , MarwickTH . Myocardial dysfunction in hypertensive patients with isolated diastolic heart failure is reversible.A randomized trial of aldosterone antagonism. European Heart Journal2004;25(Suppl S):47-8. ">Mottram 2004</a>; <a href="./references#CD012721-bbs2-0022" title="Orea-TejedaA , Colin-RamirezE , Castillo-MartinezL , Asensio-LafuenteE , Corzo-LeonD , Gonzalez-ToledoR , et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Revista de Investigacion Clinica2007;59(2):103-7. ">Orea‐Tejeda 2007</a>; <a href="./references#CD012721-bbs2-0039" title="WangYC , YuCC , ChiuFC , TsaiCT , LaiLP , HwangJJ , et al. Aldosterone antagonism increases post-exercise recruitment of systolic myocardial motion over left ventricular lateral wall in hypertensive patients with diastolic heart failure. Circulation2010;122(2):P1059. ">Wang 2010</a>) did not contribute any outcome data of interest for this review. </p> <section id="CD012721-sec-0067"> <h5 class="title">Cardiovascular mortality</h5> <p>We included five studies that reported cardiovascular mortality (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>). Of these, two studies reported that no deaths occurred (<a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>). We included data from three studies in the meta‐analysis (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>) (RR 0.90, 95% CI 0.74 to 1.11; 4070 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0009" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> also reported a hazard ratio (HR 0.90, 95% CI 0.73 to 1.12; 3445 participants). </p> </section> <section id="CD012721-sec-0068"> <h5 class="title">Heart failure hospitalisation</h5> <p>We included six studies that reported heart failure hospitalisation (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). Of these, three studies reported no hospitalisations due to heart failure(<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). We included data from three studies in the meta‐analysis (<a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>) (11% of participants in the intervention arm versus 14% in the control arm, RR 0.82, 95% CI 0.69 to 0.98; 3714 participants; NNTB 41; I² = 22%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0010" title="">Analysis 2.2</a>). </p> <p>Hazard ratios for time to first heart failure hospitalisation were reported for two studies (<a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>) (HR 0.82, 95% CI 0.69 to 0.98; 3670 participants; I² = 59%; <a href="./references#CD012721-fig-0011" title="">Analysis 2.3</a>). The substantial heterogeneity was explained by differences in population characteristics (<a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>, LVEF ≥ 45%; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> subgroup, LVEF 40% to 45%). </p> </section> <section id="CD012721-sec-0069"> <h5 class="title">Hyperkalaemia</h5> <p>We included six studies that reported hyperkalaemia (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>) (16% of participants in the intervention arm versus 8% in the control arm, RR 2.11, 95% CI 1.77 to 2.51; 4291 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD012721-fig-0012" title="">Analysis 2.4</a>). </p> </section> <section id="CD012721-sec-0070"> <h5 class="title">All‐cause mortality</h5> <p>We included eight studies that reported all‐cause mortality (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). Of these, three studies reported that no deaths occurred (<a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0033" title="ACTRN12614000088640. Spironolactone in myocardial dysfunction with reduced exercise capacity [Effects of spironolactone or control on LV filling pressure and exercise capacity in patients with myocardial dysfunction with reduced exercise capacity]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365563 (data submitted 6 January 2014). KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Beneficial effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction-SpironolacTone in myocaRdial dysfunction with reduced exercise capacity (STRUCTURE). European Heart Journal2016;37:795. KosmalaW , RojekA , Przewlocka-KosmalaM , WrightL , MysiakA , MarwickTH . Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. Journal of the American College of Cardiology2016;68(17):1823-34. KosowskiW , KabajM , Przewlocka-KosmalaM , MysiakA , MarwickT , KosmalaW . Usefulness of myocardial work measurement in the assessment of left ventricular systolic reserve response to spironolactone in heart failure with preserved ejection fraction. Kardiologia Polska2018;76(Suppl 1):120-1. ">STRUCTURE</a>). The meta‐analysis included data from five studies (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) (RR 0.91, 95% CI 0.78 to 1.06; 4207 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0013" title="">Analysis 2.5</a>). </p> <p><a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> also reported a hazard ratio (HR 0.91, 95% CI 0.77 to 1.08; 3445 participants). </p> </section> <section id="CD012721-sec-0071"> <h5 class="title">Quality of life</h5> <p>We included six studies that reported quality of life (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>). <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> reported quality of life in a report by Lewis 2016, but the end scores per treatment arm were not provided. We contacted the investigators and await details. </p> <p>Three studies (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) reported total MLFHQ scores and were pooled for analysis (MD 0.84, 95% CI ‐2.30 to 3.98; 511 participants; I² = 0%; low‐certainty evidence; <a href="./references#CD012721-fig-0016" title="">Analysis 2.8</a>). <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a> and <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a> reported KCCQ results and were pooled (MD ‐0.78, 95% CI ‐28.02 to 26.46; 92 participants; I² = 86%; <a href="./references#CD012721-fig-0015" title="">Analysis 2.7</a>). The substantial heterogeneity could not be explained. </p> <p>All five studies that used MLHFQ and KCCQ were pooled (SMD 0.05, 95% CI ‐0.23 to 0.34; 603 participants; I² = 50%; <a href="./references#CD012721-fig-0014" title="">Analysis 2.6</a>). The substantial heterogeneity could not be explained. </p> </section> <section id="CD012721-sec-0072"> <h5 class="title">Withdrawal due to adverse event</h5> <p>Five studies reported this outcome (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0019" title="EudraCT 2013-000867-10. Effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, excercise capacity and quality of life questionaire [Effects of aldosterone antagonism in heart failure with preserved ejection fraction (HF-PEF): cardiac MRI, echocardiography, exercise physiology &amp; quality of life assessment]. www.clinicaltrialsregister.eu/ctr-search/trial/2013-000867-10/GB (first received 13 February 2014). McDiarmidAK , SwobodaPP , ErhayiemB , BounfordKA , BijstervelP , TyndallK , et al. Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. Journal of the American Heart Association2020;9:e011521. ">McDiarmid 2020</a>; <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) and contributed to the meta‐analysis (RR 1.10, 95% CI 1.00 to 1.21; 4037 participants; five studies; I² = 0%; <a href="./references#CD012721-fig-0017" title="">Analysis 2.9</a>). </p> </section> </section> <section id="CD012721-sec-0073"> <h4 class="title">ACEIs versus placebo or no treatment</h4> <p>We included eight studies involving a total of 2061 participants that assessed ACEIs versus placebo or no treatment. The main outcomes for this comparison are presented in <a href="./full#CD012721-tbl-0003">summary of findings Table 3</a>. The findings for this comparison were driven by <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>. Two studies (<a href="./references#CD012721-bbs2-0004" title="AronowWS , KronzonI . Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. American Journal of Cardiology1993;71(7):602-4. ">Aronow 1993</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>) did not contribute any outcome data of interest for this review. </p> <section id="CD012721-sec-0074"> <h5 class="title">Cardiovascular mortality</h5> <p>Three studies reported cardiovascular mortality (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>). <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a> reported that no deaths occurred. <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a> and <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> contributed data to the meta‐analysis (RR 0.93, 95% CI 0.61 to 1.42; 945 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0018" title="">Analysis 3.1</a>). </p> <p><a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> also reported a hazard ratio (HR 0.98, 95% CI 0.63 to 1.52; 850 participants). </p> </section> <section id="CD012721-sec-0075"> <h5 class="title">Heart failure hospitalisation</h5> <p>Three studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) reported heart failure hospitalisation and were pooled for analysis (RR 0.86, 95% CI 0.64 to 1.15; 1019 participants; I² = 0%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0019" title="">Analysis 3.2</a>). </p> <p><a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> also reported a hazard ratio (HR 0.86, 95% CI 0.61 to 1.20; 850 participants). </p> </section> <section id="CD012721-sec-0076"> <h5 class="title">Hyperkalaemia</h5> <p><a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a> reported hyperkalaemia (RR 5.27, 95% CI 0.26 to 106.16; 74 participants; very low‐certainty evidence; <a href="./references#CD012721-fig-0020" title="">Analysis 3.3</a>). </p> </section> <section id="CD012721-sec-0077"> <h5 class="title">All‐cause mortality</h5> <p>We included six studies that reported all‐cause mortality (<a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>). <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a> reported that no deaths occurred. Five studies (<a href="./references#CD012721-bbs2-0006" title="AronowWS , MercandoAD , EpsteinS . Effect of benazepril on complex ventricular arrhythmias in older patients with congestive heart failure, prior myocardial infarction, and normal left ventricular ejection fraction. American Journal of Cardiology1998;81(11):1368-70. ">Aronow 1998</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) contributed to the meta‐analysis (RR 1.04, 95% CI 0.75 to 1.45; 1187 participants; five studies; I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0021" title="">Analysis 3.4</a>). </p> <p><a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a> also reported a hazard ratio (HR 1.09, 95% CI 0.75 to 1.58; 850 participants). </p> </section> <section id="CD012721-sec-0078"> <h5 class="title">Quality of life</h5> <p>Three studies reported quality of life assessed using the MLHFQ scale (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>; <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>). <a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a> reported quality of life assessment based on the MLHFQ scale as change from baseline per treatment arm (‐18.9 for intervention, ‐10.7 for control). We were unsuccessful in our attempts to contact study authors to obtain scores at the end of follow‐up. Two studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>) contributed to the meta‐analysis (MD ‐0.09, 95% CI ‐3.66 to 3.48; 154 participants; I² = 4%; low‐certainty evidence; <a href="./references#CD012721-fig-0022" title="">Analysis 3.5</a>). </p> <p><a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a> assessed quality of life using the McMaster quality of life questionnaire and reported end scores at six months (12.9 ± 3.1 for the intervention and 13.1 ± 4.7 for the control arm). </p> </section> <section id="CD012721-sec-0079"> <h5 class="title">Withdrawal due to adverse event</h5> <p>Four studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>; <a href="./references#CD012721-bbs2-0040" title="YuksekU , CeritL , ErenNK , ErgeneO . The effect of perindopril on echocardiographic parameters, NYHA functional class and serum NT-proBNP values in patients with diastolic heart failure. Cardiovascular Journal of Africa2019;30(4):222-7. YuksekU , HamzaD , ZehraA , UgurK , NihanKE , RidaB , et al. The effect of perindopril treatment on echocardiographic diastolic and systolic functional parameters and serum NT-proBNP values in diastolic heart failure patients. European Journal of Heart Failure. Supplements2012;11:S231. ">Yuksek 2012</a>; <a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) reported this outcome and were pooled for analysis (RR 2.52, 95% CI 0.49 to 12.87; 1127 participants; four studies; I² = 58%; <a href="./references#CD012721-fig-0023" title="">Analysis 3.6</a>). </p> </section> </section> <section id="CD012721-sec-0080"> <h4 class="title">ARBs versus placebo or no treatment</h4> <p>We included eight studies involving a total of 8755 participants that assessed ARBs versus placebo or no treatment. The main outcomes for this comparison are included in <a href="./full#CD012721-tbl-0004">summary of findings Table 4</a>. The findings for this comparison were driven by two studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>). Three trials (<a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0007" title="2005-001306-87. Effects of Candesartan Cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function. www.clinicaltrialsregister.eu/ctr-search/trial/2005-001306-87/IT (first received 2 February 2007). AleksovaA , MassonS , MaggioniAP , LucciD , UrsoR , StaszewskyL , et al. Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy2012;26(6):131-43. NCT00843154. Efficacy of candesartan on brain natriuretic peptide levels in subjects with chronic heart failure (CANDHEART) [Effects of candesartan cilexetil vs standard therapy on serum levels of brain natriuretic peptide in patients suffering from chronic heart failure with depressed and preserved systolic function]. clinicaltrials.gov/ct2/show/NCT00843154 (First posted 13 February 2009). ">CandHeart</a>; <a href="./references#CD012721-bbs2-0015" title="KasamaS , ToyamaT , KumakuraH , TakayamaY , IchikawaS , SuzukiT , et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. Journal of the American College of Cardiology2005;45(5):661-7. ">Kasama 2005</a>) did not contribute any outcome data of interest for this review. </p> <section id="CD012721-sec-0081"> <h5 class="title">Cardiovascular mortality</h5> <p>Four studies reported this outcome (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>). <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a> reported that no deaths occurred. Three studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>) contributed to the meta‐analysis (RR 1.02, 95% CI 0.90 to 1.14; 7254 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD012721-fig-0024" title="">Analysis 4.1</a>). </p> <p>Two studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>) were also pooled for an analysis of hazard ratio (HR 1.00, 95% CI 0.89 to 1.13; 7148 participants; <a href="./references#CD012721-fig-0025" title="">Analysis 4.2</a>). </p> </section> <section id="CD012721-sec-0082"> <h5 class="title">Heart failure hospitalisation</h5> <p>Three studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>) reported this outcome and were pooled for analysis (RR 0.92, 95% CI 0.83 to 1.02; 7254 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD012721-fig-0026" title="">Analysis 4.3</a>). </p> <p>Two studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>) were also pooled for analysis  of hazard ratio (HR 0.90, 95% CI 0.80 to 1.01; 7148 participants; <a href="./references#CD012721-fig-0027" title="">Analysis 4.4</a>). </p> </section> <section id="CD012721-sec-0083"> <h5 class="title">Hyperkalaemia</h5> <p>Two studies reported this outcome and were pooled for analysis (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>) (0.9% of participants in the intervention group and 0.5% in the control group; RR 1.88, 95% CI 1.07 to 3.33; 7148 participants; high‐certainty evidence; <a href="./references#CD012721-fig-0028" title="">Analysis 4.5</a>). </p> </section> <section id="CD012721-sec-0084"> <h5 class="title">All‐cause mortality</h5> <p>Five studies reported this outcome (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>). <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a> reported that no deaths occurred. Four studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>) contributed to the meta‐analysis (RR 1.01, 95% CI 0.92 to 1.11; 7964 participants; I² = 0%; high‐certainty evidence; <a href="./references#CD012721-fig-0029" title="">Analysis 4.6</a>). For the <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a> trial, data for participants with LVEF ≥ 50% were analysed according to the definition of HFpEF used in this trial. </p> <p>Two studies (<a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0034" title="MiuraM , SakataY , MiyataS , ShibaN , TakahashiJ , NochiokaK , et al. Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circulation Journal2016;80(10):2155-64. MiuraM , SakataY , MiyataS , TadakiS , UshigomeR , YamouchiT , et al. The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Journal of Cardiac Failure2015;21(10):S159. NCT00417222. Supplemental benefit of angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT). clinicaltrials.gov/ct2/show/NCT00417222 (first posted 29 December 2006). SakataY , ShibaN , TakahashiJ , MiyataS , NochiokaK , MiuraM , et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. European Heart Journal2015;36(15):915-23. ">SUPPORT</a>) were also pooled for analysis of hazard ratio (HR 0.99, 95% CI 0.88 to 1.12; 4838 participants; <a href="./references#CD012721-fig-0030" title="">Analysis 4.7</a>). </p> </section> <section id="CD012721-sec-0085"> <h5 class="title">Quality of life</h5> <p>Four studies reported this outcome (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>). <a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a> reported quality of life (MLHFQ) in a study report (Lewis 2007): however, end scores per treatment arm were not provided. Three studies (<a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) contributed to the meta‐analysis for MLHFQ (MD 0.41, 95% CI ‐0.86 to 1.67; 3117 participants; I² = 19%; high‐certainty evidence; <a href="./references#CD012721-fig-0031" title="">Analysis 4.8</a>). </p> </section> <section id="CD012721-sec-0086"> <h5 class="title">Withdrawal due to adverse event</h5> <p>Four studies (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>; <a href="./references#CD012721-bbs2-0011" title="CUHK_CCT00035. Treatment of diastolic heart failure: the role of blockade of the renin-angiotensin system. A comparison of diuretics with an angiotensin converting enzyme inhibitor, angiotensin receptor blockade or diuretics alone. www2.ccrb.cuhk.edu.hk/registry/public/15 (trial registration 7 September 2005). YipGW , WangM , WangT , ChanS , FungJW , YeungL , et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart2008;94(5):573-80. ">Hong Kong DHF</a>; <a href="./references#CD012721-bbs2-0012" title="AdabagS , RectorTS , AnandIS , McMurrayJJ , ZileM , KomajdaM , et al. A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure2014;16(11):1175-82. AnandIS , RectorTS , ClelandJG , KuskowskiM , McKelvieRS , PerssonH , et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circulation2011;4(5):569-77. Anonymous. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy. Cardiovascular Journal of Africa2008;19(6):337-9. BadarAA , Perez-MorenoAC , HawkinsNM , JhundPS , BruntonAP , et al. Clinical characteristics and outcomes of patients with coronary artery disease and angina: analysis of the irbesartan in patients with heart failure and preserved systolic function trial. Circulation2015;8(4):717-24. BlandonJA . ARBs and the impact of worsening renal function in heart failure patients with preserved EF. Cardiology Review2014;30(6):no pagination. BohmM , PerezAC , JhundPS , ReilJC , KomajdaM , ZileMR , et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). European Journal of Heart Failure2014;16(7):778-87. CannonJA , ShenL , JhundPS , AnandIS , KomajdaM , McKelvieRS , et al. Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. European Journal of Heart Failure2016;18(8):1021-31. CarsonP , AnandI , WinS , ZileM , HaasM , LittleW , et al. Why are patients with heart failure and preserved ejection fraction hospitalized? Data from i-preserve. Circulation2013;128(Suppl 22):A15844. CarsonP , MassiePM , McKelvieR , McMurrayJ , KomajdaM , ZileM , et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. Journal of Cardiac Failure2005;11(8):576-85. CarsonPE , ZileM , McMurrayJ , McKelvieR , KomajdaM , HetzelS , et al. Heart failure with preserved ejection fraction: Mortality risk post first hospitalization - Data from I-preserve. Journal of the American College of Cardiology2010;55(10):A141.E1321. ChowSL , KrumH , O'BarrSA , ZileM , CarsonP , KomajdaM , et al. Markers of extracellular matrix turnover and risk of death in patients with heart failure with preserved ejection fraction: Results from I-PRESERVE. Journal of the American College of Cardiology2015;65(10):A969. DammanK , PerezAC , AnandIS , KomajdaM , McKelvieRS , ZileMR , et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. Journal of the American College of Cardiology2014;64(11):1106-13. EzekowitzJA , McAlisterFA . ACP Journal Club. Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction. Annals of Internal Medicine2009;150(10):JC5-10. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. Journal of Cardiac Failure2017;23(1):20-8. GandhiPU , ChowSL , RectorTS , KrumH , GagginHK , McMurrayJJ , et al. The prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction: Results from irbesartan in heart failure and preserved ejection fraction (I-preserve) trial. Circulation2015;132(Suppl 3):A14299. HaassM , KitzmanDW , AnandIS , MillerA , ZileMR , MassieBM , et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circulationi2011;4(3):324-31. KaoDP , LewseyJD , AnandIS , MassieBM , ZileMR , CarsonPE , et al. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. European Journal of Heart Failure2015;17(9):925-35. KaoDP , LewseyJK , MassieBM , McMurrayJ , CarsonPE , AnandIS , et al. Characterization of heart failure patients with preserved ejection fraction in the I-PRESERVE trial who have improved outcomes with irbesartan therapy. European Journal of Heart Failure. Supplements2012;11:S4. KomajdaM , CarsonPE , HetzelS , McKelvieR , McMurrayJ , PtaszynskaA , et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circulation2011;4(1):27-35. KristensenSL , JhundPS , KoberL , McKelvieRS , ZileMR , AnandIS , et al. Relative importance of history of heart failure hospitalization and N-Terminal pro-b-type Natriuretic Peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Failure2015;3(6):478-86. KristensenSL , JhundPS , KoberL , PreissD , KjekshusJ , McKelvieRS , et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure2015;17(2):169-76. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. KristensenSL , MogensenUM , JhundPS , PetrieMC , PreissD , WinS , et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: A report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). Circulation2017;135(8):724-35. KrumH , ElsikM , SchneiderH , PtaszynskaA , BlackM , CarsonP , et al. Peripheral collagen markers predict all-cause mortality and cardiovascular hospitalisation in patients with heart failure and preserved ejection fraction: Results of the I-PRESERVE collagen sub-study. Heart, Lung and Circulation2010;19:S77-8. KrumH , ElsikM , SchneiderHG , PtaszynskaA , BlackM , CarsonPE , et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circulation2011;4(5):561-8. LamCS , CarsonPE , AnandIS , RectorTS , KuskowskiM , KomajdaM , et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failurewith Preserved Ejection Fraction (I-PRESERVE) trial. Circulation2012;5(5):571-8. MassieBM , CarsonPE , McMurrayJJ , KomajdaM , McKelvieR , ZileM , et al. Irbesartan in patients with heart failure and preserved ejection fraction. New England Journal of Medicine2008;359(23):2456-67. McKelvieRS , KomajdaM , McMurrayJ , ZileM , PtaszynskaA , DonovanM , et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. Journal of Cardiac Failure2010;16(2):128-34. McMurrayJJ , CarsonPE , KomajdaM , McKelvieR , ZileMR , PtaszynskaA , et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. European Journal of Heart Failure2008;10(2):149-56. NCT00095238. Irbesartan in heart failure with preserved systolic function (I-Preserve). clinicaltrials.gov/show/NCT00095238 (first posted 2 November 2004). OluleyeO , WinS , RectorT , KomadjaM , ZileM , McKelvieR , et al. Risk of clinical outcomes and baseline atrial fibrillation: Irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circulation2013;128(22):A15893. OluleyeOW , RectorTS , WinS , McMurrayJJ , ZileMR , KomajdaM , et al. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circulationi2014;7(6):960-6. RectorTS , CarsonPE , AnandIS , McMurrayJJ , ZileMR , McKelvieRS , et al. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. Circulation2012;5(2):217-25. SchillaciG , PucciG , PirroM . Irbesartan for heart failure with preserved ejection fraction. New England Journal of Medicine2009;360(12):1258; author reply 1258-9. SchneiderHG , KrumH , ElsikM , PtaszynskaA , BlackM , AnandI , et al. I-preserve sub-study: Plasma collagen markers in the prediction of death and hospitalisation in patients with heart failure and preserved ejection fraction. Clinical Chemistry and Laboratory Medicine2011;49:S337. TeerlinkJR , ZileMR , WhiteM , MillerAB , Lopez-SendonJ , LittleWC , et al. Acute coronary syndromes in patients with heart failure with preserved ejection fraction: A harbinger of death?JACC2010;55(10):A38.E368. WinS , AnandI , McMurrayJ , ZileM , McKelvieR , KomajdaM , et al. Morbidity and mortality in diabetics with heart failure and a preserved ejection fraction: Results from the i-preserve trial. Journal of the American College of Cardiology2013;61(10):E706. ZileMR , GaaschWH , AnandI , HaassM , LittleWC , MullerA , et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from irbesartan heart failure with preserved ejection fraction study (I-Preserve) trial. European Heart Journal2009;30:867. ZileMR , GaaschWH , AnandIS , HaassM , LittleWC , MillerAB , et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation2010;121(12):1393-405. ZileMR , GottdienerJS , HetzelSJ , McMurrayJJ , KomajdaM , McKelvieR , et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation2011;124(23):2491-501. ">I‐PRESERVE</a>; <a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) reported this outcome and contributed to the meta‐analysis (16% of participants in the intervention arm versus 13% in the control arm; RR 1.22, 95% CI 1.09 to 1.36; 7406 participants; I² = 0%; <a href="./references#CD012721-fig-0032" title="">Analysis 4.9</a> NNTH = 33). </p> </section> </section> <section id="CD012721-sec-0087"> <h4 class="title">ARNIs versus usual care</h4> <p>We included three studies that involved a total of 7702 participants. The main outcomes for this comparison are included in <a href="./full#CD012721-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD012721-sec-0088"> <h5 class="title">Cardiovascular mortality</h5> <p>One study, <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>, reported proportional hazards and total event counts for CV mortality; a hazard ratio (HR) of 0.95 (95% CI 0.79 to 1.16) was reported and we calculated the risk ratio (RR), based on the total event counts, as 0.96 (95% CI 0.79 to 1.15; 4796 participants; moderate‐certainty evidence; <a href="./references#CD012721-fig-0033" title="">Analysis 5.1</a>). </p> </section> <section id="CD012721-sec-0089"> <h5 class="title">Heart failure hospitalisation</h5> <p><a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> and <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> reported data for first hospitalisation due to HF, which led to a RR of 0.89 (95% CI 0.80 to 1.00; 7362 participants; I² = 56%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0034" title="">Analysis 5.2</a>). </p> <p><a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> and <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> also reported HRs for time to first hospitalisation due to HF, which gives a pooled effect of HR 0.87 (95% CI 0.76 to 0.99; 7362 participants; two studies; I² = 82%; <a href="./references#CD012721-fig-0035" title="">Analysis 5.3</a>). </p> </section> <section id="CD012721-sec-0090"> <h5 class="title">Hyperkalaemia</h5> <p>Two studies (<a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>; <a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a>) reported this outcome (RR 0.88, 95% CI 0.77 to 1.01; 5054 participants; two studies; I² = 8%; moderate‐certainty evidence; <a href="./references#CD012721-fig-0036" title="">Analysis 5.4</a>). </p> </section> <section id="CD012721-sec-0091"> <h5 class="title">All‐cause mortality</h5> <p>The three studies reported data for all‐cause mortality (RR 0.97, 95% CI 0.84 to 1.11; 7663 participants; three studies; high‐certainty evidence; <a href="./references#CD012721-fig-0037" title="">Analysis 5.5</a>). </p> </section> <section id="CD012721-sec-0092"> <h5 class="title">Quality of life</h5> <p><a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a> reported change from baseline for the KCCQ overall summary score for the intervention arm (n = 118) as 11.25 (2.185) and the control arm (n = 116) as 11.31 (2.183), and summarised the findings as "no difference in KCCQ score between treatment groups". </p> <p><a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> reported a difference of the clinical summary score KCCQ between treatment arms as 1.0 (0.0 to 2.1). </p> <p><a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> reported "KCCQ improved in both treatment groups, with an early benefit of S/V that was no longer significant after 24 week". </p> </section> <section id="CD012721-sec-0093"> <h5 class="title">Withdrawal due to adverse event</h5> <p>The three studies reported withdrawals due to adverse events (RR 1.02, 95% CI 0.91 to 1.14; 7663 participants; three studies; I<sup>2</sup> = 62%; <a href="./references#CD012721-fig-0038" title="">Analysis 5.6</a>). </p> </section> </section> <section id="CD012721-sec-0094"> <h4 class="title">Subgroup analyses</h4> <p>We did not have sufficient data to allow for meaningful subgroup analyses.</p> </section> <section id="CD012721-sec-0095"> <h4 class="title">Sensitivity analyses</h4> <p>We conducted a sensitivity analysis by only including studies assessed at low risk of bias. Across comparisons, the estimates were not significantly changed, with the exception of BBs, where no effect on cardiovascular mortality was observed (one low risk of bias study (<a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>): RR 0.81, 95% CI 0.50 to 1.29; versus overall analysis of three studies: RR 0.78, 95% CI 0.62 to 0.99). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012721-sec-0096" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012721-sec-0096"></div> <section id="CD012721-sec-0097"> <h3 class="title" id="CD012721-sec-0097">Summary of main results</h3> <p>We examined the evidence for the effects of BBs and RAAS inhibitors for the treatment of HFpEF. We included 41 trials, reported in 234 publications that involved a total of 26,059 participants. We identified 13 ongoing trials with treatment arms that include interventions assessed in this review. A further nine studies await assessment. </p> <p>We performed a pooled analysis for the outcomes of cardiovascular and all‐cause mortality, heart failure hospitalisation, quality of life and hyperkalaemia. For most studies, we use the MLHFQ instrument to evaluate quality of life outcomes since this was the most frequently reported measure, except for ARNI trials that used KCCQ. </p> <p>Withdrawals due to adverse events were inconsistently reported; these data could not be included in 'Summary of findings' tables. </p> <p>We conducted a sensitivity analysis by including only studies assessed with overall low risk of bias. The effect estimates were not significantly changed, except for BBs. </p> <section id="CD012721-sec-0098"> <h4 class="title">BBs</h4> <p>A total of 10 included studies (3087 participants) assessed BBs compared with placebo or no intervention. We performed meta‐analyses including up to four studies and 1105 participants. The results suggested that treatment may improve cardiovascular mortality, however, the quality of evidence was low due to imprecision and risk of bias. When we performed a sensitivity analysis by including only studies with a low overall risk of bias, the effects on cardiovascular mortality did not persist. The two largest studies (<a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a>) reported high rates of study drug discontinuation due to intolerance rather than adverse events, which may have attenuated any true treatment effects. A recent individual participant meta‐analysis found evidence that beta‐blockers improve LVEF and prognosis in heart failure patients with LVEF  40 to 49%, but not in those with  LVEF over 50% (<a href="./references#CD012721-bbs2-0377" title="ClelandJG , BuntinKV , FlatherMD , AltmanDG , HolmesJ , CoatsAJ , et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal2018;39(1):26-35.">Cleland 2018</a>). </p> </section> <section id="CD012721-sec-0099"> <h4 class="title">MRAs</h4> <p>A total of 13 studies (4459 participants) assessed MRA compared with placebo or no intervention. We combined evidence from up to six trials and 4291 participants in meta‐analyses. We found that treatment with MRA reduces the risk of heart failure hospitalisation but found little or no effect on cardiovascular and all‐cause mortality; however the certainty of evidence was moderate and uncertainty remains over these treatment effects. As expected, MRA treatment was associated with an increased risk of hyperkalaemia; potassium monitoring is therefore required in people being treated using MRA. A large, registry‐randomised clinical outcomes trial of spironolactone for HFpEF is ongoing and due to complete in 2022 (<a href="./references#CD012721-bbs2-0370" title="NCT02901184. Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT). clinicaltrials.gov/show/NCT02901184 (first posted 15 September 2016). ">NCT02901184</a>: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction, SPIRRIT). </p> </section> <section id="CD012721-sec-0100"> <h4 class="title">ACEIs</h4> <p>A total of eight included studies (2062 participants) assessed ACEIs versus placebo or no intervention. We conducted a meta‐analysis of data from up to five trials and 1187 participants. We found that there was probably little or no effect on cardiovascular mortality, all‐cause mortality, heart failure hospitalisation or quality of life. Data on hyperkalaemia were limited. No large clinical trials (more than 1000 participants) were available and the certainty of evidence was assessed as moderate due to imprecision. The effectiveness of ACEI therapy in the treatment of people with HFpEF remains unclear. </p> </section> <section id="CD012721-sec-0101"> <h4 class="title">ARBs</h4> <p>A total of eight included studies (8755 participants) assessed ARB therapy for people with HFpEF, with the evidence certainty assessed as high. We combined evidence from up to four trials and 7964 participants for meta‐analysis and found little or no overall difference on the outcomes of cardiovascular mortality, all‐cause mortality, heart failure hospitalisation or quality of life. The CHARM study found a beneficial effect on HF hospitalisation based on a time‐to‐event analysis; the strength of this association was increased in a subsequent analysis, based on recurrent events (<a href="./references#CD012721-bbs2-0408" title="RogersJK , PocockSJ , McMurrayJJ , GrangerCB , MichelsonEL , ÖstergrenJ , et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. European Journal of Heart Failure2014;16(1):33-40.">Rogers 2014</a>). As expected, ARB treatment was associated with an increased risk of hyperkalaemia; potassium monitoring is therefore required. </p> </section> <section id="CD012721-sec-0102"> <h4 class="title">ARNIs</h4> <p>Three studies (7696 participants) assessed ARNI therapy for people with HFpEF. Only one study (<a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a>) provided usable data for cardiovascular mortality and found little or no difference between the treatment groups (moderate‐certainty evidence). Meta‐analysis of risk ratio for first heart failure hospitalisation from the <a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> and <a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> trials indicated a probable modest benefit, however there was little or no effect on cardiovascular or all‐cause mortality. </p> <p>A pooled analysis suggested that a slightly reduced risk of hyperkalaemia in ARNI versus standardized usual care or placebo comparison overall (moderate‐certainty evidence). </p> </section> </section> <section id="CD012721-sec-0103"> <h3 class="title" id="CD012721-sec-0103">Overall completeness and applicability of evidence</h3> <p>This review provides the most comprehensive appraisal of the evidence to date. We included 41 studies (234 reports) that involved 26,059 participants. The included trials assessed BBs (10 studies, 3087 participants), MRAs (13 studies, 4459 participants), ACEIs (eight studies, 2061 participants), ARBs (eight studies, 8755 participants) and ARNIs (three studies, 7702 participants). </p> <p>We searched clinical trials registries and identified 13 ongoing clinical trials, several of which have potential to influence the review findings. We also identified nine studies that were classified as <a href="./references#CD012721-bbs1-0003" title="">Studies awaiting classification.</a> There was insufficient information to determine whether these studies met our inclusion criteria. These studies were mostly small and it is therefore unlikely that they would influence the results of this review. In total, we identified 234 reports of 41 trials, nine studies awaiting classification, and 13 ongoing trials, compared with a total of 22 identified by <a href="./references#CD012721-bbs2-0423" title="ZhengSL , ChanFT , NabeebaccusAA , ShahAM , McDonaghT , OkonkoDO , et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart2018;104:407-15.">Zheng 2018</a> for the same comparisons. </p> <p>The LVEF threshold for defining the HFpEF trial populations varied among the included studies. This may contribute to indirectness, with implications for the applicability of the evidence. Nine studies included participants with an ejection fraction cut‐off of 40%, 12 used 45%, 15 used 50%, and one used 55%. <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a> included participants with preserved ejection fraction but did not specify the cut‐off. <a href="./references#CD012721-bbs2-0030" title="Cohen-SolalA , KotechaD , vanVeldhuisenDJ , BabalisD , BohmM , CoatsAJ , et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure2009;11(9):872-80. deBoerRA , DoehnerW , van derHorstIC , AnkerSD , BabalisD , RougthonM , et al. Influence of diabetes mellitus and hyperglycemia on prognosis in patients &gt; or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). American Journal of Cardiology2010;106(1):78-86. FlatherMD , ShibataMC , CoatsAJS , Van VeldhuisenDJ , ParkhomenkoA , BorbolaJ , et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal2005;26:215-25. GhioS , MagriniG , SerioA , KlersyC , FuciliA , RonaszekiA , KarpatiP , et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. European Heart Journal2006;27(5):562-8. LindseyML , FreemanGL . Beta-blockade in heart failure: adding SENIORS to the mix. European Heart Journal2006;27(5):506-7. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcome in elderly heart failure patients with preserved and reduced ejection fraction treated with nebivolol: data from SENIORS trial. European Heart Journal2014;35:339. Montero-Perez-BarqueroM , FlatherM , RoughtonM , CoatsA , BohmM , Van VeldhuisenDJ , et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. European Journal of Heart Failure2014;16(9):1009-15. MulderBA , vanVeldhuisenDJ , CrijnsHJ , BohmM , Cohen-SolalA , BabalisD , et al. Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS. European Journal of Heart Failure2012;14(10):1171-8. ShibataMC , FlatherMD , BohmM , BorbolaJ , Cohen-SolalA , DumitrascuD , et al. Study of the effects of nebivolol intervention on outcomes and reshospitalisation in seniors with heart failure (SENIORS). International Journal of Cardiology2002;86:77-85. vanVeldhuisenDJ , Cohen-SolalA , BohmM , AnkerSD , BabalisD , RoughtonM , et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology2009;53(23):2150-8. Von HaehlingS , BabalisD , RoghtonM , Van VeldhuisenDJ , Poole-WilsonPA , FlatherM , et al. Prevalence of anaemia and the effects of nebivolol on haemoglobin values in patients with chronic heart failure: Results from the SENIORS database. Journal of Cardiac Failure2009;15(6):S96. vonHaehlingS , vanVeldhuisenDJ , RoughtonM , BabalisD , deBoerRA , CoatsAJ , et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. European Journal of Heart Failure2011;13(6):656-63. ">SENIORS</a> reported a subgroup of participants with LVEF greater than 40%, and for <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a> we obtained outcomes for a subgroup with LVEF greater than 40%. </p> <p>The included studies had enrolment start dates from 1997 to 2014. In more recent studies, B‐type natriuretic peptides have been used as a key inclusion criterion to improve the specificity of the HFpEF population and enrich the trial populations for people at higher risk for clinical outcomes (e.g. <a href="./references#CD012721-bbs2-0008" title='EudraCT 2007-003070-26. Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.. www.clinicaltrialsregister.eu/ctr-search/trial/2007-003070-26/DE (first entered 10 July 2007). NCT00775840. Efficacy of candesartan on symptomatic heart failure in treating diabetic and hypertensive patients [Candesartan "added" therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicenter clinical phase III study investigating the effects on NT-proBNP over 6 months]. clinicaltrials.gov/ct2/show/NCT00775840 (first received 20 October 2008). '>CAN‐DHF</a>; <a href="./references#CD012721-bbs2-0018" title="MakG , LedwidgeM , MurphyNF , PhelanD , DawkinsI , WatsonC , et al. Eplerenone favourably alters collagen metabolism in diastolic heart failure. European Heart Journal2009;30:866. MakGJ , LedwidgeMT , WatsonCJ , PhelanDM , DawkinsIR , MurphyN , et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Journal of the American College of Cardiology2009;54(18):1674-82. NCT00505336. The effect of eplerenone and atorvastatin on markers of collagen turnover in diastolic heart failure. clinicaltrials.gov/show/NCT00505336 (first posted 23 July 2007). ">Mak 2009</a>; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>). Similarly, new measures of diastolic function have been included in more recent studies to increase the specificity (e.g. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a>; <a href="./references#CD012721-bbs2-0027" title="ClelandJG , TaylorJ , FreemantleN , GoodeKM , RigbyAS , TenderaM . Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. European Journal of Heart Failure2012;14(5):487-94. ClelandJG , TenderaM , AdamusJ , FreemantleN , GrayCS , LyeM , et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure1999;1(3):211-7. ClelandJG , TenderaM , AdamusJ , FreemantleN , PolonskiL , TaylorJ . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal2006;27(16):2338-45. McMurrayJ . Renin angiotensin blockade in heart failure with preserved ejection fraction: The signal gets stronger. European Heart Journal2006;27(19):2257-9. WidimskyJ . Managing diastolic heart failure. Results of PEP-CHF [Lecba diastolickeho srdecniho selhani. Vysledky studie PEP-CHF]. Cor Vasa2006;48(11):403-7. ">PEP‐CHF</a>). We noted considerable clinical heterogeneity among study populations with respect to comorbidities and cardiovascular therapies at baseline, which may influence the applicability of the evidence. </p> </section> <section id="CD012721-sec-0104"> <h3 class="title" id="CD012721-sec-0104">Quality of the evidence</h3> <p>We used the GRADE method to assess evidence certainty for the outcomes of cardiovascular mortality, all‐cause mortality, heart failure hospitalisation, quality of life (assessed using the MLHFQ), and hyperkalaemia. For BBs, evidence certainty for clinical outcomes (cardiovascular mortality, all‐cause mortality and heart failure hospitalisation) ranged from low to very low. In the combined analysis, most participants were from a subgroup of a single large trial; the other included studies were small, with high or unclear risk of bias. </p> <p>For MRAs, the <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> study contributed the majority of participants to the meta‐analysis, for which the overall evidence certainty for clinical outcomes was assessed as moderate. We noted differences in participant populations among the included studies (<a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a>, LVEF greater than 45%; <a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>, LVEF equal to or greater than 50%; <a href="./references#CD012721-bbs2-0003" title="BoccanelliA , CaciatoreG , MuredduGF , deSimoneG , ClemenzaF , De MariaR , et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). Journal of Cardiovascular Medicine2007;8(9):683-91. BoccanelliA , MuredduGF , CacciatoreG , ClemenzaF , Di LenardaA , GavazziA , et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. European Journal of Heart Failure2009;11(1):68-76. CacciatoreG , BoccanelliA , MuredduGF , MaggioniAP , LatiniR , MassonS , et al. The AREA IN-CHF trial (antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure): rationale and design. Italian Heart Journal2005;6(Suppl 1):66S-74S. De SimoneG , ChinaliM , MuredduGF , CacciatoreG , LucciD , LatiniR , et al. Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases2011;21(10):783-91. NCT00403910. Antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure. AREA IN-CHF study [Phase 3 study of antiremodeling effect of aldosterone receptors blockade with canrenone in mild chronic heart failure]. clinicaltrials.gov/ct2/show/NCT00403910 (first received 27 November 2006. ">AREA IN‐CHF</a>, LVEF 40% to 45%) and it is reported that ejection fraction is a modifier of treatment effect for MRAs (<a href="./references#CD012721-bbs2-0412" title="Solomon ScottD , Claggett Brian, Lewis EldrinF , Desai Akshay, Anand Inder, Sweitzer NancyK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62.">Solomon 2016</a>). Notably, a post hoc analysis of the <a href="./references#CD012721-bbs2-0037" title="AnandIS , ClaggettB , LiuJ , ShahAM , RectorTS , ShahSJ , et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC. Heart Failure2017;5(4):241-52. AnandIS , SolomonSD , ClaggettB , ShahSJ , O'MearaE , BoineauR , et al. Prognostic value of baseline BNP and NT-proBNP and its interaction with spironolactone in patients with heart failure and preserved ejection fraction in the TOPCAT trial. Circulation2015;132:no pagination. BajajNS , ClaggettB , LewisE , DesaiA , FangJ , OmearaE , et al. Influence of left ventricular ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction: The TOPCAT trial. Journal of the American College of Cardiology2017;69(11):884. BristowMR , EncisoJS , GershBJ , GradyC , RiceMM , SinghS , et al. Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations. JACC: Basic to Translational Science2016;1(3):180-9. DesaiAS , LewisEF , LiR , SolomonSD , AssmannSF , BoineauR , et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. American Heart Journal2011;162(6):966-72. DesaiAS , LiuJ , ClaggettB , BristowM , FlegJ , LewisEF , et al. Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved ejection fraction with spironolactone. European Heart Journal2015;36:662-3. GirerdN , FerreiraJP , RossignolP , ZannadF . A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. European Journal of Heart Failure2016;18(12):1411-4. HamoCE , HeitnerJF , PfefferMA , KimHY , KenwoodCT , AssmannSF , et al. Baseline distribution of participants with depression and impaired quality of life in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. Circulation2015;8(2):268-77. HegdeS , ClaggettB , ShahAM , LewisEF , AnandIS , ShahSJ , et al. Physical activity and prognosis in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation2017;21:21. JosephJ , ClaggettBC , AnandIS , FlegJL , HuynhT , DesaiAS , et al. QRS duration is a predictor of adverse outcomes in heart failure with preserved ejection fraction. JACC. Heart Failure2016;4(6):477-86. JosephJ , ClaggettBL , AnandIS , FlegJL , HuynhT , DesaiAS , et al. Prolonged QRS duration predicts outcomes in heart failure with preserved ejection fraction. Circulation2015;132(Suppl 3):A11159. KaoDP , FlintKM , MerrillM . Spironolactone reduces all-cause mortality in women but not men with heart failure with preserved ejection fraction enrolled in TOPCAT from the Americas. European Journal of Heart Failure2017;19:530-1. KellyJ , GrangerCB . Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. Annals of Internal Medicine2014;161(8):JC6. Kelsey FlingK , MerrillM , KaoD . Sex differences in long-term health status in heart failure with preserved ejection fraction. European Journal of Heart Failure2017;19:530-1. KitaiT , GrodinJ , Wilson TangWH . Paradoxical impact of proportional pulse pressure on mortality in patients with heart failure with preserved ejection fraction. Journal of the American College of Cardiology2017;69(11):882. KristensenSL , KoberL , JhundPS , SolomonSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. MerrillM , SweitzerNK , LindenfeldJA , KaoKP . Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial. JACC Heart Failure2019;7(3):228-38. MorawietzH , BornsteinSR . Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;371(2):181. NCT00094302. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)]. clinicaltrials.gov/ct2/show/NCT00094302 (First posted 15 October 2004). NeefsJ , Van Den BergNW , BergerWR , MeulendijksER , GrootJR . Risk of atrial fibrillation in heart failure with preserved ejection fraction: results from the treatment of cardiac function with an aldosterone antagonist (TOPCAT). European Heart Journal2017;38(Suppl 1):759-60. NeefsJ , vanden BergNW , KrulSP , BoekholdtSM , deGrootJR . Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. American Journal of Cardiovascular Drugs2020;20:73-80. O'MearaE , KenwoodCT , AnandIS , DesaiAS , De DenusS , SweitzerNK , et al. Anemia in heart failure with preserved ejection fraction: insights from the Topcat trial. Circulation2015;132(Suppl 3):A17975. O'NealWT , SandesaraP , PatelN , VenkateshS , Samman-TahhanA , HammadahM , et al. Echocardiographic predictors of atrial fibrillation in patients with heart failure with preserved ejection fraction. European Heart Journal - Cardiovascular Imaging2017;30:30. O'NealWT , SandesaraPB , Samman-TahhanA , KelliHM , HammadahM , SolimanEZ . Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. European Journal of Preventive Cardiology2017;24(11):1212-9. PfefferMA , BraunwaldE . Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist. JAMA Cardiology2016;1(1):7-8. PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardia Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42. PfefferMA , McKinlayS , PittB . Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). Circulation2013;128(24):2709. PittB , PfefferMA , AssmannS , BoineauR , AnandIS , ClaggettB , et al. Spironolactone for heart failure with preserved ejection fraction. New England Journal of Medicine2014;370(15):1383-92. SandesaraPB , HammadahM , Samman-TahhanA , KelliHM , O'NealWT . Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction. Clinical Cardiology2017;26:26. SantosAB , RocaGQ , ClaggettB , SweitzerNK , ShahSJ , AnandIS , et al. Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circulation2016;9(4):e002763. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Impaired systolic function assessed by strain imaging predicts cardiovascular morbidity and mortality in heart failure with preserved ejection fraction. Circulation2014;130(Suppl 1):A16989. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , LiuL , et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;132(5):402-14. ShahAM , ClaggettB , SweitzerNK , ShahSJ , AnandIS , O'MearaE , et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction. Circulation. Heart Failure2014;7(5):740-51. ShahAM , ClaggettB , SweitzerNK , ShahSJ , DeswalA , AnandIS , et al. Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation2015;8(6):1052-8. ShahAM , ShahSJ , AnandIS , SweitzerNK , O'MearaE , HeitnerJF , et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circulation2014;7(1):104-15. ShahSJ , HeitnerJF , SweitzerNK , AnandIS , KimHY , HartyB , et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circulation2013;6(2):184-92. SolomonSD , ClaggettB , LewisEF , DesaiA , AnandI , SweitzerNK , et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal2016;37(5):455-62. VardenyO , ClaggettB , VaduganathanM , BeldhuisI , RouleauJ , O'MearaE , et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC: Heart Failure2019;7(12):1022-8. VardenyO , VaduganathanM , ClaggettB , DesaiAS , AnandIS , ShahSJ , et al. Influence of age on the efficacy and safety of spironolactone in heart failure with preserved ejection fraction. Journal of Cardiac Failure2019;25(8S):S12. ">TOPCAT</a> study reported important differences in the placebo event rates among participants enrolled from the Americas (Argentina, Brazil, Canada, USA) and participants enrolled from Russia and Georgia (<a href="./references#CD012721-bbs2-0401" title="PfefferMA , ClaggettB , AssmannSF , BoineauR , AnandIS , ClausellN , et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac FunctionHeart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation2015;131(1):34-42.">Pfeffer 2015</a>). Furthermore, a pharmacology substudy of participants at 12 months (206 participants from USA and Canada; 160 participants from Russia) found that drug metabolites were undetectable in a greater proportion of participants from Russia, compared with participants from the USA and Canada (30% versus 3%, P &lt; 0.001) (<a href="./references#CD012721-bbs2-0380" title="deDenusS , O'MearaE , DesaiAS , ClaggettB , LewisEF , LeclairG , et al. Spironolactone metabolites in TOPCAT - new insights into regional variation. New England Journal of Medicine2017;376(17):1690-2.">de Denus 2017</a>). A geographical subgroup analysis suggested possible clinical benefit from spironolactone in HFpEF in participants who were enrolled in the Americas (United States, Canada, Brazil, Argentina; cardiovascular mortality HR 0.74, 95% CI 0.57 to 0.97; all‐cause mortality HR 0.83, 95% CI 0.68 to 1.02; heart failure hospitalisation HR 0.82, 95% CI 0.67 to 0.99). These findings will be investigated further in the ongoing SPIRRIT study (<a href="./references#CD012721-bbs2-0370" title="NCT02901184. Spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT). clinicaltrials.gov/show/NCT02901184 (first posted 15 September 2016). ">NCT02901184</a>). </p> <p>For ARBs, several large trials contributed a large number of events to the meta‐analysis for the clinical outcomes of mortality and heart failure hospitalisation, and the evidence certainty was high. For ACEIs, fewer trials were included in the combined analysis, event numbers were low and the evidence certainty was assessed as moderate. For BBs, the certainty of evidence was low due to small study sizes and risk of bias. </p> <p>For ARNIs, the evidence certainty was classified as moderate for all outcomes except for all cause mortality and quality of life which was of high certainty; the cardiovascular mortality and hyperkalaemia outcomes were downgraded due to imprecision. </p> </section> <section id="CD012721-sec-0105"> <h3 class="title" id="CD012721-sec-0105">Potential biases in the review process</h3> <p>Although we conducted a comprehensive search of major databases, it is possible we missed studies on clinical trials registers, studies that had not been reported, or both. Where information on relevant subgroups or outcomes were not reported, we attempted to contact the study authors; however, only a limited number of responses were received. Given the small number of included studies per analysis, we were unable to formally assess the presence of publication bias. </p> </section> <section id="CD012721-sec-0106"> <h3 class="title" id="CD012721-sec-0106">Agreements and disagreements with other studies or reviews</h3> <p>The results of this study were largely consistent with those from a comprehensive review of the evidence for BBs and RAAS inhibitors in people with HFpEF (<a href="./references#CD012721-bbs2-0423" title="ZhengSL , ChanFT , NabeebaccusAA , ShahAM , McDonaghT , OkonkoDO , et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart2018;104:407-15.">Zheng 2018</a>); however, important differences were noted. Our analysis included more studies for each comparison, but the additional studies were small and did not significantly alter the overall effect estimates. In contrast to <a href="./references#CD012721-bbs2-0423" title="ZhengSL , ChanFT , NabeebaccusAA , ShahAM , McDonaghT , OkonkoDO , et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart2018;104:407-15.">Zheng 2018</a>, we did not find clear evidence of an effect of BB treatment on all‐cause mortality, after the exclusion of studies with an unclear or high risk of bias. Our findings were consistent with meta‐analyses of ACE and ARB (<a href="./references#CD012721-bbs2-0391" title="KhanMS , FonarowGC , KahnH , GreeneSJ , AnkerSD , GheorghiadeM , et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure2017;4:402-8.">Khan 2017</a>) and MRA (<a href="./references#CD012721-bbs2-0394" title="LiS , ZhangX , DongM , GongS , ShangZ , JiaX , et al. Effects of spironolactone in heart failure with preserve ejection fraction: a meta-analysis of randomized controlled trials. Medicine2018;97:35.">Li 2018</a>). </p> <p>A recent individual‐patient level analysis of RCTs of BBs in HF, across the full spectrum of LVEF, reported evidence that BBs reduced cardiovascular mortality; the benefit was observed for heart failure patients in sinus rhythm at all levels of LVEF less than 50%, including patients with LVEF 40% to 49% (<a href="./references#CD012721-bbs2-0377" title="ClelandJG , BuntinKV , FlatherMD , AltmanDG , HolmesJ , CoatsAJ , et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal2018;39(1):26-35.">Cleland 2018</a>). Similarly, an individual patient‐level pooled analysis of PARADIGM‐HF and PARAGON‐HF found evidence of effect modification of ARNI efficacy by LVEF, but with benefit on heart failure hospitalisation and cardiovascular mortality probably extending to patients with mid‐range LVEF (40% to 49%) (<a href="./references#CD012721-bbs2-0413" title="SolomonSD , VaduganathanM , ClaggettBL , PackerM , ZileM , SwedbergK , et al. Sacubitril/Valsartan across the spectrum of ejection fraction in heart failure. Circulation2020;141(5):352-61.">Solomon 2020</a>). Consistent with these reports, a study‐level meta‐analysis of trials of RAAS interventions found beneficial effects on heart failure hospitalisation in patients with LVEF greater than 50%; however, increasing LVEF was associated with a decreasing trend for benefit (<a href="./references#CD012721-bbs2-0383" title="EmdinCA , CallenderT , CaoJ , McMurrayJJ , RahimiK . Meta-analysis of large-scale randomized trials to determine the effectiveness of inhibition of the renin-angiotensin aldosterone system in heart failure. American Journal of Cardiology2015;116(1):155-61.">Emdin 2015</a>). Data from the CHARM‐preserved study suggests a similar benefit of ARB on heart failure hospitalisation in patients with LVEF 40% to 49%, compared to those with LVEF less than 40% (<a href="./references#CD012721-bbs2-0009" title="BadarAA , Perez-MorenoAC , HawkinsNM , BruntonAP , JhundPS , WongCM , et al. Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure2015;17(2):196-204. BelloNA , ClaggettB , DesaiAS , McMurrayJJ , GrangerCB , YusufS , et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circulation2014;7(4):590-5. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology2012;59(20):1785-95. CastagnoD , SkaliH , TakeuchiM , SwedbergK , YusufS , GrangerCB , et al. Incidence and predictors of stroke in patients with chronic heart failure: Does left ventricular function Matter? Insights From the CHARM Program. Circulation2011;124(Suppl 21):A17352. ChangSM , GrangerCB , JohanssonPA , KosolcharoenP , McMurrayJJ , MichelsonEL , et al. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2010;12(7):738-45. Cohen-SolalA , McMurrayJJ , SwedbergK , PfefferMA , PuuM , SolomonSD , et al. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal2008;29(24):3022-8. ColomboGL , CaruggiM , OttoliniC , MaggioniAP . Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management2008;4(1):223-34. DammanK , SolomonSD , PfefferMA , SwedbergK , YusufS , YoungJB , et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. European Journal of Heart Failure2016;18(12):1508-17. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerC , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. European Journal of Heart Failure2013;34:284. DesaiAS , ClaggettB , PfefferMA , BelloN , FinnPV , GrangerCB , et al. Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. Circulation2014;7(6):895-902. DubreySW . Angiotensin II receptor antagonists in the treatment of heart failure: Background to and design of the CHARM study. British Journal of Cardiology2002;9(5):280-2,284,286. FruhwaldFM , VavrovskyAD . Resource utilization and costs for candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme for the Austrian setting. Value in Health2011;14(7):A379. GersteinHC , SwedbergK , CarlssonJ , McMurrayJJ , MichelsonEL , OlofssonB , et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine2008;168(15):1699-704. Grewal, J, McKelvieRS , PerssonH , TaitP , CarlssonJ , SwedbergK , et al. Usefulness of N-terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. American Journal of Cardiology2008;102(6):733-7. GuptaDK , CastagnoD , GrangerCB , YusufS , SwedbergK , McMurrayJ , et al. Prognostic impact of an ischemic etiology of chronic heart failure across the spectrum of ejection fractions in the charm program. Journal of Cardiac Failure2012;18(8):S78. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. European Journal of Heart Failure2007;9(5):510-7. HawkinsNM , WangD , McMurrayJJ , PfefferMA , SwedbergK , GrangerCB , et al. Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. Heart2007;93(1):59-64. HawkinsNM , WangD , PetrieMC , PfefferMA , SwedbergK , GrangerCB , et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure2010;12(6):557-65. JacksonCE , SolomonSD , GersteinHC , ZetterstrandS , OlofssonB , MichelsonEL , et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet2009;374(9689):543-50. KochsiekK . Angiotensin receptor blockers in heart failure. CHARM Study [Angiotensinrezeptorblocker bei Herzinsuffizienz]. Internist2004;45(9):1063-7. KristensenSL , KoberL , JhundPS , SolomSD , KjekshusJ , McKelvieRS , et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation2015;131(1):43-53. LundLH , ClaggettB , LiuJ , LamCS , JhundPS , RosanoGM , et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure2018;20:1230-9. MacDonaldMR , PetrieMC , VaryaniF , OstergrenJ , MichelsonEL , YoungJB , et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal2008;29(11):1377-85. McKelvieRS . The CHARM program: the effects of candesartan for the management of patients with chronic heart failure. Expert Review Cardiovascular Therapy2009;7(1):9-16. McMurrayJ , OstergrenJ , PfefferM , SwedbergK , GrangerC , YusufS , et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure2003;5(3):261-70. McMurrayJJ . Angiotensin inhibition in heart failure. Journal of the Renin Angiotensin Aldosterone System2004;5(Suppl 1):S17-22. MeredithPA , OstergrenJ , AnandI , PuuM , SolomonSD , MichelsonEL , et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. Journal of the American College of Cardiology2008;52(24):2000-7. MeyerTE . The candesartan in heart failure-assessment of reduction in mortality and morbidity-preserved trial. Current Cardiology Reports2004;6(3):197-8. MitchellGF , ArnoldJM , DunlapME , O'BrienTX , MarchioriG , WarnerE , et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. European Journal of Heart Failure2006;8(2):191-7. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , LangCC , RogerS , et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation2006;113(7):986-94. O'MearaE , ClaytonT , McEntegartMB , McMurrayJJ , PinaIL , GrangerCB , et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation2007;115(24):3111-20. OlssonLG , SwedbergK , DucharmeA , GrangerCB , MichelsonEL , McMurrayJJ , et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. Journal of the American College of Cardiology2006;47(10):1997-2004. OstergrenJB . Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Supplements2006;24(1):S3-7. PerssonH , LonnE , EdnerM , BaruchL , LangCC , MortonJJ , et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. Journal of the American College of Cardiology2007;49(6):687-94. PocockSJ , McMurrayJJ , DobsonJ , YusufS , GrangerCB , MichelsonEL , et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal2008;29(21):2641-50. RappJA , GheroghiadeM . Role of neurohormonal modulators in heart failure with relatively preserved systolic function. Heart Failure Clinic2005;1(1):77-93. SicaDA . ACE inhibitor intolerance and lessons learned from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) trials. Congestive Heart Failure2004;10(3):160-4. SolomonSD , AnavekarN , SkaliH , McMurrayJJ , SwedbergK , YusufS , et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulationi2005;112(24):3738-44. SolomonSD , DobsonJ , PocockS , SkaliH , McMurrayJJ , GrangerCB , et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation2007;116(13):1482-7. SomonSD , WangD , FinnP , SkaliH , ZornoffL , McMurrayJJ , et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.[Erratum appears in Circulation. 2005 Jan 25;111(3):378]. Circulation2004;110(15):2180-3. SwedbergK , PfefferM , GrangerC , HeldP , McMurrayJ , OhlinG , et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and design. Journal of Cardiac Failure1999;5(3):276-82. WoisetschlagerC . Congress of the European Society of Cardiology 2003 in Vienna. Convincing results of candesartan in heart failure. Journal fur Kardiologie2003;10(10):453-4. YusufS , PfefferMA , SwedbergK , GrangerCB , HeldP , McMurrayJJ , et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003;362(9386):777-81. ">CHARM‐Preserved</a>). </p> <p>Taken together, these findings suggest that the beneficial effects of BBs and RAAS inhibitors may extend beyond patients with LVEF less than 40% to include patients with LVEF 40% to 49%; however, evidence for this group of patients is currently limited. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012721-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012721-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012721-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012721-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)" data-id="CD012721-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)" data-id="CD012721-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 3: All‐cause mortality (RR)" data-id="CD012721-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 3: All‐cause mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 4: Quality of life (Minnesota)" data-id="CD012721-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 4: Quality of life (Minnesota) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 5: Withdrawal due to adverse event" data-id="CD012721-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Beta‐blockers versus placebo or no treatment, Outcome 5: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)" data-id="CD012721-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)" data-id="CD012721-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (HR)" data-id="CD012721-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (HR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 4: Hyperkalaemia" data-id="CD012721-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 4: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 5: All‐cause mortality (RR)" data-id="CD012721-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 5: All‐cause mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 6: Quality of life" data-id="CD012721-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 6: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 7: Quality of life (KCCQ)" data-id="CD012721-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 7: Quality of life (KCCQ) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 8: Quality of life (Minnesota)" data-id="CD012721-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 8: Quality of life (Minnesota) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event" data-id="CD012721-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Mineralocorticoid receptor antagonists versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)" data-id="CD012721-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR)" data-id="CD012721-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 2: Heart failure hospitalisation (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 3: Hyperkalaemia" data-id="CD012721-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 3: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 4: All‐cause mortality (RR)" data-id="CD012721-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 4: All‐cause mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 5: Quality of life (Minnesota)" data-id="CD012721-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 5: Quality of life (Minnesota) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 6: Withdrawal due to adverse event" data-id="CD012721-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Angiotensin converting enzyme inhibitors versus placebo or no treatment, Outcome 6: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR)" data-id="CD012721-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 1: Cardiovascular mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 2: Cardiovascular mortality (HR)" data-id="CD012721-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 2: Cardiovascular mortality (HR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (RR)" data-id="CD012721-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 3: Heart failure hospitalisation (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 4: Heart failure hospitalisation (HR)" data-id="CD012721-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 4: Heart failure hospitalisation (HR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 5: Hyperkalaemia" data-id="CD012721-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 5: Hyperkalaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 6: All‐cause mortality (RR)" data-id="CD012721-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 6: All‐cause mortality (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 7: All‐cause mortality (HR)" data-id="CD012721-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 7: All‐cause mortality (HR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 8: Quality of life (Minnesota)" data-id="CD012721-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 8: Quality of life (Minnesota) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event" data-id="CD012721-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Angiotensin receptor blockers versus placebo or no treatment, Outcome 9: Withdrawal due to adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 1: Cardiovascular mortality (RR)" data-id="CD012721-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 1: Cardiovascular mortality (RR)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 2: Heart failure hospitalisation, first (RR)" data-id="CD012721-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 2: Heart failure hospitalisation, first (RR) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 3: Heart failure hospitalisation (HR)" data-id="CD012721-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 3: Heart failure hospitalisation (HR)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 4: Hyperkalaemia" data-id="CD012721-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 4: Hyperkalaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 5: All‐cause mortality (RR)" data-id="CD012721-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 5: All‐cause mortality (RR)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012721-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/urn:x-wiley:14651858:media:CD012721:CD012721-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: ARNI versus usual care, Outcome 6: Withdrawal due to adverse event" data-id="CD012721-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_t/tCD012721-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: ARNI versus usual care, Outcome 6: Withdrawal due to adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/media/CDSR/CD012721/image_n/nCD012721-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012721-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> beta‐blockers<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with beta‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range 21 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.62 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1046<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three additional studies (<a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>; <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>; <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/>(107 to 171) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 6 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.47 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>449<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up unclear for <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a>. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a> reported that no hospitalisation due to heart failure occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/>(55 to 133) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> <p>follow‐up: mean 3.2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>1 6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012721-bbs2-0013" title="HoriM . Rationale and design of a randomized trial to assess the effects of β-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiac Failure2005;11(7):542-7. UMIN: C000000318. Japanese Diastolic Heart Failure Study. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000411 (Registered 1 February 2006). YamamotoK , OrigasaH , HoriM . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). European Journal of Heart Failure2013;15(1):110-8. YamamotoK , OrigasaH , HoriM . Left atrial dilatation as a predictive factor of beneficial response to carvedilol in patients with HFPEF: A finding from the Japanese Diastolic Heart Failure study (J-DHF). European Heart Journal2013;34:161. YamamotoK , OrigasaH , SuzukiY , TakahashiT , ShinozakiT , WatanabeT , et al. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). Journal of Cardiology2014;63(6):424-31. ">J‐DHF</a> reported one participant in the intervention group (N = 120) experienced hyperkalaemia but did not report on this outcome for the control group. No further data were available from any of the other studies. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow‐up: range 21 months to 3.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.67 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1105<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up unclear for <a href="./references#CD012721-bbs2-0001" title="AdamyanKG , TumasyanLR . Independent and additive influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Heart Journal2010;31:850. TumasyanLR , AdamyanKG . Influence of statin and beta-blocker on long-term prognosis in patients with chronic heart failure and preserved systolic function. European Journal of Heart Failure Supplements2010;9:S23-4. ">Adamyan 2010</a>. <a href="./references#CD012721-bbs2-0010" title="2004-000746-20. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity and left ventricular function of the patients with diastolic dysfunction (ELANDD). www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000746-20 (date submitted 9 October 2006). ConraadsVM , MetraM , KampO , De KeulenaerGW , PieskeB , ZamoranoJ , et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. European Journal of Heart Failure2012;14(2):219-25. KampO , MetraM , De KeulenaerGW , PieskeB , ConraadsV , ZamoranoJ , et al. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clinical Research in Cardiology2010;99:75-82. ">ELANDD</a>, <a href="./references#CD012721-bbs2-0035" title="BergstromA , AnderssonB , EdnerM , NylanderE , PerssonH , DahlstromU . Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). European Journal of Heart Failure2004;6(4):453-61. ">SWEDIC</a> and <a href="./references#CD012721-bbs2-0036" title="TakedaY , FukutomiT , SuzukiS , YamamotoK , OgataM , KondoH , et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. American Journal of Cardiology2004;94:448-53. ">Takeda 2004</a> reported that no deaths occurred. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>243 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>199 per 1000<br/>(163 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) was 24</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/>(9.05 lower to 7.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower = better, 5 point difference considered to be clinically meaningful</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to study limitations (unclear selection bias in most studies). </p> <p><sup>2</sup>Downgraded by one level due to imprecision (concerns about the smaller study being more precise than the larger study). </p> <p><sup>3</sup>Downgraded by two levels due to imprecision (few events and wide CI). </p> <p><sup>4</sup>Downgraded by two levels due to imprecision (very small sample size). </p> <p><sup>5</sup>Downgraded by one level due to suspected publication bias (this is a patient‐relevant outcome that is not reported in most studies). </p> <p><sup>6</sup>Downgraded by two levels due to suspected publication bias (incomplete reporting). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Beta‐blockers compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012721-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>MRAs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> MRAs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MRAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range 12 months to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/>(0.74 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4070<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two additional trials (<a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(65 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 24 weeks to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.69 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3714<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Three additional trials (<a href="./references#CD012721-bbs2-0002" title="BorlaugBA . Heart failure: Aldosterone antagonism for HFpEF. Nature Reviews Cardiology2013;10(5):244-6. Djawid HashemiD , DettmannL , TrippelTD , BobenkoA , GelbrichG , LindhorstR , et al. Economic impact of heart failure with preserved ejection fraction: Insights from the prospective, randomized placebo-controlled ALDO-DHF trial. European Journal of Heart Failure2017;19:155. DurstewitzK , HolzendorfV , WachterR , GelbrichG , StahrenbergR , HasenfussG , et al. Galectin-3 in heart failure with preserved ejection fraction-the effects of chronic aldosterone receptor blockade (the ALDO-DHF trial). Internist2013;54(2):104-5. EdelmannF , GelbrichG , DuvinageA , StahrenbergR , BehrensA , PrettinC , et al. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. International Journal of Cardiology2013;169(6):408-17. EdelmannF , HolzendorfV , WachterR , NolteK , SchmidtAG , Kraigher-KrainerE , et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. European Journal of Heart Failure2015;17(2):214-23. EdelmannF , SchmidtAG , GelbrichG , BinderL , Herrmann-LingenC , HalleM , et al. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). European Journal of Heart Failure2010;12(8):874-82. EdelmannF , WachterR , PieskeB . Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply. JAMA2013;310(2):205-7. EdelmannF , WachterR , SchmidtAG , Kraigher-KrainerE , ColantonioC , KamkeW , et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA2013;309(8):781-91. ElguindyAM . ALDO-DHF &amp; Paramount. Global Cardiology Science &amp; Practice2013;2(2012):12-4. EudraCT 2006-002605-31. Aldosterone receptor blockade in diastolic heart failure. A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002605-31/DE (first received 30 November 2006). ISRCTN94726526. Aldosterone receptor blockade in diastolic heart failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure. www.isrctn.com/ISRCTN94726526 (first received 7 November 2006). LundLH , StahlbergM . Aldosterone inhibition in patients with heart failure with preserved ejection fraction. JAMA2013;10(2):205. TrippelTD , Regitz-ZagrosekV , GelbrichG , Mueller-ScholdenL , WachterR , DungenHD , et al. Gender specific treatment effects of spironolactone in diastolic heart failure: Insight from ALDO-DHF. European Journal of Heart Failure2016;18:130. ">ALDO‐DHF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>; <a href="./references#CD012721-bbs2-0038" title="NCT00123955. PIE II: pharmacological intervention in the elderly II [Exercise intolerance in elderly diastolic heart failure]. clinicaltrials.gov/show/NCT00123955 (first posted 26 July 2005). UpadhyaB , HundleyWG , BrubakerPH , MorganTM , StewartKP , KitzmanDW . Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. Journal of the American Geriatric Society2017;19:19. ">Upadhya 2017</a>) reported that no hospitalisation due to heart failure occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000<br/>(94 to 134) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hyperkalaemia<br/>follow‐up: range 24 weeks to 3.3 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.11<br/>(1.77 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4291<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two trials defined hyperkalaemia ≥ 5.5 mEg/L</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>175 per 1000<br/>(146 to 208) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/>follow‐up: range 9 months to 3.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.91<br/>(0.78 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4207<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two additional trials (<a href="./references#CD012721-bbs2-0028" title="DeswalA , RichardsonP , BozkurtB , MannDL . Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). Journal of Cardiac Failure2011;17(8):634-42. NCT00108251. Aldosterone antagonism in diastolic heart failure. clinicaltrials.gov/ct2/show/NCT00108251 (first posted 15 April 2005). ">RAAM‐PEF</a>; <a href="./references#CD012721-bbs2-0017" title="KurrelmeyerKM , AshtonY , XuJ , NaguehSF , Torre-AmioneG , DeswalA . Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. Journal of Cardiac Failure2014;20(8):560-8. NCT00206232. Novel treatment for diastolic heart failure in women. clinicaltrials.gov/show/NCT00206232 (first posted 21 September 2005). ">Kurrelmeyer 2014</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000<br/>(104 to 141) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: range 9 months to 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 20 to 25</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.84 higher<br/>(2.30 lower to 3.98 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lower = better, 5 points are considered a clinically significant difference</p> <p>We did not pre‐specify which QoL scale was to be reported in the 'Summary of findings' table. To aid comparisons among 'Summary of findings' tables we chose to include the Minnesota Living with Heart Failure questionnaire and not the SMD across two scales </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>MRAs:</b> Mineralocorticoid receptor antagonists; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision. </p> <p><sup>2</sup>Downgraded by one level due to study limitations (one trial was open label). </p> <p><sup>3</sup>Downgraded by one level due to imprecision (small sample size). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mineralocorticoid receptor antagonists (MRAs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012721-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ACEIs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ACEIs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ACEI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range mean 12 months to mean 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.61 to 1.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>945<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>81 per 1000<br/>(53 to 123) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range 6 months to 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.64 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1019<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(8 to 15) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hyperkalaemia</p> <p>follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 (1 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One trial (<a href="./references#CD012721-bbs2-0041" title="ZiM , CarmichaelN , LyeM . The effect of quinapril on functional status of elderly patients with diastolic heart failure. Cardiovascular Drugs and Therapy2003;17:133-9. ">Zi 2003</a>) reported 2 events in the intervention group (N = 36), 0 events in the control group (N = 38) (RR 5.27, 95% CI 0.26 to 106.16) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow‐up: range mean 6 months to mean 26.2 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.04<br/>(0.75 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1187<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0016" title="KitzmanDW , HundleyWG , BrubakerPH , MorganTM , MooreJB , StewartKP , et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circulation2010;3(4):477-85. NCT01411735. Evaluation of enalapril versus placebo in patients with diastolic heart failure (PIE-I). clinicaltrials.gov/show/NCT01411735 (first posted 8 August 2011). ">Kitzman 2010</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(77 to 148) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 10.9 to 29</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/>(3.66 lower to 3.48 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale: 0 to 105, lower = better, 5 point difference considered clinically relevant</p> <p>One trial (<a href="./references#CD012721-bbs2-0032" title="MareevV , SkvortsovA , DanielyanM , BelenkovYU . Quinapril in treatment of ambulatory patients with arterial hypertension and congestive heart failure and preserved systolic left ventricular function. (Results from the SNEGOVIK Study). European Journal of Heart Failure. Supplement2011;10:S78. ">SNEGOVIK</a>) reported mean change from baseline of ‐19.8 for intervention and ‐10.7 for control </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ACEIs:</b> Angiotensin‐converting enzyme inhibitors; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision (wide CI). </p> <p><sup>2</sup>Downgraded by one level due to study limitations (risk of bias (open label)). </p> <p><sup>3</sup>Downgraded by one level due to imprecision (low sample size). </p> <p><sup>4</sup>Downgraded by one level due to study limitations (unclear selection bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Angiotensin‐converting enzyme inhibitors (ACEIs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012721-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARBs compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ARBs<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ARBs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)<br/>follow‐up: range mean 12 months to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.90 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7254<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(118 to 149) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heart failure hospitalisation (RR)<br/>follow‐up: range mean 12 months to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.83 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7254<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>171 per 1,‐000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1,‐000<br/>(142 to 174) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hyperkalaemia<br/>follow‐up: range 36.6 months to 49.5 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.88<br/>(1.07 to 3.33) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5 per 1,000<br/>(3 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)<br/>follow up: range 1 years to 4.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.01<br/>(0.92 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7964<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One additional trial (<a href="./references#CD012721-bbs2-0026" title="CVAL489B2401. Novartis Clinical Trial Results Database. www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2460 (date accessed 30 November 2017). NCT00171106. Efficacy and safety of valsartan versus placebo on exercise tolerance in patients with heart failure [A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of valsartan on exercise time in subjects with symptomatic diastolic heart failure]. clinicaltrials.gov/show/NCT00171106 (first posted 15 September 2005). ParthasarathyHK , PieskeB , WeisskopfM , AndrewsCD , BrunelP , StruthersAD , et al. A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction. European Journal of Heart Failure2009;11(10):980-9. ">Parthasarathy 2009</a>) reported that no deaths occurred </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1,‐000<br/>(66 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (MLHFQ): from 0 to 105<br/>follow‐up: range mean 13.8 weeks to mean 49.5 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean quality of life (MLHFQ) ranged from 10.9 to 31.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.41 higher<br/>(0.86 lower to 1.67 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3117<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale: 0 to 105, lower = better, 5 point difference considered clinically relevant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ARBs:</b> Angiotensin receptor blockers; <b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>MLHFQ:</b> Minnesota Living with Heart Failure Questionnaire; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Angiotensin receptor blockers (ARBs) compared to placebo or no treatment for chronic heart failure with preserved ejection fraction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012721-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Angiotensin receptor neprilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ARNIs compared to usual care for chronic heart failure with preserved ejection fraction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with chronic heart failure with preserved ejection fraction<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> ARNI (sacubitril‐valsartan)<br/><b>Comparison:</b> ARB <b>(</b>valsartan) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with usual care</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ARNI</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality (RR)</p> <p>Median follow‐up: 35 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.79 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4796<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000<br/>(70 to 102) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Heart failure hospitalisation, first (RR)</p> <p>Range of follow‐up: 24 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.89</p> <p>(0.80 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>7362</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>126 per 1,000</p> <p>(113 to 142)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hyperkalaemia</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.88<br/>(0.77 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>5054<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>147 per 1,000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>129 per 1,000<br/>(113 to 148) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality (RR)</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>(RR 0.97</p> <p>CI 0.84 to 1.11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7663<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>138 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1,000<br/>(117 to 153) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> <p>Range of follow‐up: 36 weeks to 35 months</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p><a href="./references#CD012721-bbs2-0025" title="Biering-SorensenT , ShahA , ClaggettB , ZileM , PieskeB , Pieske-KraigherE , et al. The angiotensin receptor neprilysin inhibitor (ARNI), sacubitril/valsartan, improves left ventricular myocardial deformation in heart failure with preserved ejection fraction (PARAMOUNT trial). JACC2018;71(11):2665. EudraCT 2009-010208-27. A twelve-week, randomized, double-blind, multi-center,parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2009-010208-27/IT (first entered 6 May 2009). JanuzziJL , ClaggettB , LiuJ , ShahA , ZileM , PieskeB , et al. Abstract 17434: insulin-like growth factor binding protein-7 as a biomarker of diastolic dysfunction: results from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) study. Circulation2017;136:A17434. NCT00887588. LCZ696 compared to valsartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. clinicaltrials.gov/ct2/show/NCT00887588 (first posted 13 August 2015). SolomonSD , ZileM , PieskeB , VoorsA , ShahA , Kraigher-KrainerE , et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet2012;380:1387-95. ZileMR , JhundPS , BaicuCF , ClaggettBL , PieskeB , VoorsAA , et al. Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study. Circulation. Heart Failure2016;9(1):e002551. ">PARAMOUNT</a> reported change from baseline for the KCCQ overall summary score for the intervention arm (n =118) as 11.25 (2.185) and the control arm (n = 116) as 11.31 (2.183) and summarised the findings as "no difference in KCCQ score between treatment groups". </p> <p><a href="./references#CD012721-bbs2-0023" title="ChandraA , VaduganathanM , LewisEF , ClaggettBL , RizkalaAR , WangW , et al. Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial. JACC: Heart Failure2019;7(10):862-74. EUCTR2013-001747-31. A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. www.clinicaltrialsregister.eu/ctr-search/trial/2013-001747-31/ES (first entered 10 January 2014). McMurrayJJ , JacksonAM , LamCS , RedfieldMM , AnandIS , GeJ , et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation2020;141:338-51. NCT01920711. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). clinicaltrials.gov/ct2/show/NCT01920711 (first posted 12 August 2013). SolomonSD , McMurrayJJ , AnandIS , GeJ , LamCS , MaggioniAP , et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. New England Journal of Medicine2019;381(17):1609-20. SolomonSD , RizkalaAR , GongJ , WangW , AnandIS , GeJ , et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rational and design of the PARAGON-HF trial. JACC: Heart Failure2017;5(7):471-82. SolomonSD , RizkalaAR , LefkowitzMP , ShiVC , GongJ , AnavekarN , et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circulation: Heart Failure2018;11:e004962. VardenyO , ClaggettB , AnandI , VaduganathanM , PfefferMA , ZannandF , et al. Influence of age on efficacy and safety of sacubitril/valsartan in heart failure with preserved ejection fraction. JACC2020;75(11):910. ">PARAGON‐HF</a> reported a difference of the clinical summary score KCCQ between treatment arms as 1.0 (0.0 to 2.1). </p> <p><a href="./references#CD012721-bbs2-0024" title="NCT03066804. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF patients (PARALLAX) [A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction]. clinicaltrials.gov/show/NCT03066804 (first posted 28 February 2017). PieskeB . PARALLAX (slideshow). ESC Congress 2020 - The Digital Experience 30 August 2020. WachterR , ShahSJ , CowieMR , SzecsodyP , ShiV , IbramG , et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. ESC Heart Failure2020;7:856-64. ">PARALLAX</a> reported "KCCQ improved in both treatment groups, with an early benefit of S/V that was no longer significant after 24 week". </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>ARB:</b> Angiotensin receptor blocker; <b>ARNIs:</b> Angiotensin receptor neprilysin inhibitors; <b>CI:</b> Confidence interval; <b>KCCQ:</b> Kansas City Cardiomyopathy Questionnaire; <b>MD:</b> Mean difference; <b>RCT:</b> Randomised controlled trial; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Angiotensin receptor neprilysin inhibitors (ARNIs) compared to usual care for chronic heart failure with preserved ejection fraction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/full#CD012721-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012721-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Cardiovascular mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Heart failure hospitalisation (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.47, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Quality of life (Minnesota) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.07 [2.45, 133.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta‐blockers versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012721-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Mineralocorticoid receptor antagonists versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Cardiovascular mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Heart failure hospitalisation (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3714</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Heart failure hospitalisation (HR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.77, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 All‐cause mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.23, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Quality of life (KCCQ) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐28.02, 26.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Quality of life (Minnesota) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [‐2.30, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Mineralocorticoid receptor antagonists versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012721-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Angiotensin converting enzyme inhibitors versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Cardiovascular mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.61, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Heart failure hospitalisation (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 All‐cause mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.75, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Quality of life (Minnesota) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐3.66, 3.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.52 [0.49, 12.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Angiotensin converting enzyme inhibitors versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012721-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Angiotensin receptor blockers versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Cardiovascular mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Cardiovascular mortality (HR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Heart failure hospitalisation (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Heart failure hospitalisation (HR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.07, 3.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 All‐cause mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.92, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 All‐cause mortality (HR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Quality of life (Minnesota) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐0.86, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.09, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Angiotensin receptor blockers versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012721-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ARNI versus usual care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Cardiovascular mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Heart failure hospitalisation, first (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Heart failure hospitalisation (HR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Hyperkalaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.77, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 All‐cause mortality (RR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Withdrawal due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">ARNI versus usual care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012721.pub3/references#CD012721-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012721.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012721-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012721-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012721-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012721-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012721-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012721-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ro#CD012721-note-0014">Română</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012721-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012721\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012721\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012721\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012721\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012721\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012721.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012721.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012721.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012721.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012721.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714162157"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012721.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714162161"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012721.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d67e59817937d',t:'MTc0MDcxNDE2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 